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A B S T R A C T
Background
Fatigue is a common and potentially distressing symptom for patients with rheumatoid arthritis (RA), with no accepted evidence-based
management guidelines. Evidence suggests that biologic interventions improve symptoms and signs in RA as well as reducing joint
damage.
Objectives
To evaluate the effect of biologic interventions on fatigue in rheumatoid arthritis.
Search methods
We searched the following electronic databases up to 1 April 2014: Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, Current Controlled Trials Register, the National Research Register
Archive, The UKCRN Portfolio Database, AMED, CINAHL, PsycINFO, Social Science Citation Index, Web of Science, and Disser-
tation Abstracts International. In addition, we checked the reference lists of articles identified for inclusion for additional studies and
contacted key authors.
Selection criteria
We included randomised controlled trials if they evaluated a biologic intervention in people with rheumatoid arthritis and had self
reported fatigue as an outcome measure.
Data collection and analysis
Two reviewers selected relevant trials, assessed methodological quality and extracted data. Where appropriate, we pooled data in meta-
analyses using a random-effects model.
1Biologic interventions for fatigue in rheumatoid arthritis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Main results
We identified 32 studies for inclusion in this current review. Twenty studies evaluated five anti-tumour necrosis factor (anti-TNF)
biologic agents (adalimumab, certolizumab, etanercept, golimumab and infliximab), and 12 studies focused on five non-anti-TNF
biologic agents (abatacept, canakinumab, rituximab, tocilizumab and an anti-interferon gamma monoclonal antibody). All but two of
the studies were double-blind randomised placebo-controlled trials. In some trials, patients could receive concomitant disease-modifying
anti-rheumatic drugs (DMARDs). These studies added either biologics or placebo to DMARDs. Investigators did not change the dose
of the latter from baseline. In total, these studies included 9946 participants in the intervention groups and 4682 participants in the
control groups. Overall, quality of randomised controlled trials was moderate with a low to unclear risk of bias in the reporting of
the outcome of fatigue. We downgraded the quality of the studies from high to moderate because of potential reporting bias (studies
included post hoc analyses favouring reporting of positive result and did not always include all randomised individuals). Some studies
recruited only participants with early disease. The studies used five different instruments to assess fatigue in these studies: the Functional
Assessment of Chronic Illness Therapy Fatigue Domain (FACIT-F), Short Form-36 Vitality Domain (SF-36 VT), Visual Analogue
Scale (VAS) (0 to 100 or 0 to 10) and the Numerical Rating Scale (NRS). We calculated standard mean differences for pooled data
in meta-analyses. Overall treatment by biologic agents led to statistically significant reduction in fatigue with a standardised mean
difference of −0.43 (95% confidence interval (CI) −0.38 to −0.49). This equates to a difference of 6.45 units (95% CI 5.7 to 7.35)
of FACIT-F score (range 0 to 52). Both types of biologic agents achieved a similar level of improvement: for anti-TNF agents, this
stood at −0.42 (95% CI −0.35 to−0.49), equivalent to 6.3 units (95% CI 5.3 to 7.4) on the FACIT-F score; and for non-anti-TNF
agents, it was−0.46 (95% CI−0.39 to−0.53), equivalent to 6.9 units (95% CI 5.85 to 7.95) on the FACIT-F score. In most studies,
the double-blind period was 24 weeks or less. No study assessed long-term changes in fatigue.
Authors’ conclusions
Treatment with biologic interventions in patients with active RA can lead to a small tomoderate improvement in fatigue. Themagnitude
of improvement is similar for anti-TNF and non-anti-TNF biologics. However, it is unclear whether the improvement results from a
direct action of the biologics on fatigue or indirectly through reduction in inflammation, disease activity or some other mechanism.
P L A I N L A N G U A G E S U M M A R Y
Biological interventions for the management of fatigue in rheumatoid arthritis
Background
What is rheumatoid arthritis and what are biologics?
When you have rheumatoid arthritis, your immune system, which normally fights infection, attacks the lining of your joints, causing
swelling, stiffness and pain. The small joints of your hands and feet are usually affected first. There is no cure for rheumatoid arthritis
at present, so treatments aim to relieve pain and stiffness and improve your ability to move. Biologics are medications that can reduce
joint inflammation, improve symptoms and prevent joint damage.
Fatigue is an important symptom in people with rheumatoid arthritis. However, there is no consensus on themost effectivemanagement
approaches for it. A number of studies have explored the effects of biologic response modifiers (biologics) in the management of
rheumatoid arthritis and associated symptoms such as fatigue. We carried out the current review to evaluate the effects of these therapies
on fatigue in adults with rheumatoid arthritis.
Study characteristics
We searched for all research published up to 1 April 2014, finding 32 relevant studies. There were 19 studies on five anti-TNF
biologics (adalimumab, certolizumab, etanercept, golimumab and infliximab) and 12 studies on five non-anti-TNF biologics (abatacept,
canakinumab, rituximab, tocilizumab and an anti-interferon gamma monoclonal antibody).
Key results
Altogether 9,946 participants received biologics and 4,682 participants received standard therapy. All but two of the studies were
randomised placebo-controlled trials, the gold standard in terms of study quality. We compared the effects of biologics versus placebo.
In some studies, participants may have been taking standard therapy for rheumatoid arthritis at the start of the trial. In these studies,
investigators added either biologics or placebo treatment to standard therapy. Overall, treatment by biologics led to small to moderate
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reductions (9 units reduction on a 0-52 scale) in patient-reported fatigue compared with 3 units in participants treated by placebo.
It is unclear whether this improvement is due to a reduction in overall disease activity, a direct effect of the biologics or some other
mechanism.
Quality of the evidence
There may have been some potential bias in the way investigators analysed data, and some studies did not include all randomised
individuals, so we judged the quality of the evidence to be only moderate rather than high.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
All biologics for fatigue in rheumatoid arthritis
Patient or population: pat ients with fat igue in rheumatoid arthrit is
Settings: hospital, outpat ient clinics
Intervention: all biologics
Comparison: placebo or usual care
Outcomes Illustrative comparative risks* (95% CI) No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Biologics
Fatigue continuous mea-
sures
Follow-up: median 24
weeks
The mean change in fat igue
score f rom baseline in the
control for all biologics -
was 3.3 units lower of the
FACIT-F score or 3.9 lower
of the SF-36 vitality
The standardised mean dif -
ference between control
and intervent ion groups at
study endpoint for all bio-
logics was 6.45 units lower
of the FACIT-F score or 7.
65 units of SF-36 vitality
14,628
(30 studies)
⊕⊕⊕⊕
Moderatea
SMD −0.43 (95% CI −0.49
to −0.38). An SMD of 0.43
would be considered as a
moderate ef fect
This equates to a dif ference
of 6.45 units (95% CI 5.70
to 7.35) of FACIT-F score
(range 0-52) or 7.65 units
(95% CI 6.76 to 8.72) of
SF-36 vitality (range 0-100).
NNTB 5 (95% CI 5 to 6)
The mean change in fat igue
score f rom baseline in the
control for anti-TNF biolog-
ics - was 3.3 units lower of
FACIT-F score or 3.9 lower
of the SF-36 vitality
The standardised mean dif -
ference between control
and intervent ion groups at
study endpoint for anti-
TNF biologics was 6.3 units
lower of the FACIT-F score
or 7.5 units of SF-36 vitality
8946
(19 studies)
⊕⊕⊕⊕
Moderatea
SMD −0.42 (95% CI−0.35
to −0.49). An SMD of 0.
42 would be considered
as a moderate ef fect. This
equates to a dif ference of
6.3 units (95% CI: 5.3 to 7.
4) of FACIT-F score (range
0-52) or 7.5 units (95% CI
6.2 to 8.7) of SF-36 vitality
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(range 0-100). NNTB 6 (95%
CI 5 to 7)
The mean change in fat igue
score f rom baseline in the
control for non-anti-TNF bi-
ologics - was 0.5 units lower
of FACIT-F score or 0.59
lower of the SF-36 vitality
The standardised mean dif -
ference between control
and intervent ion groups at
study endpoint for non-
anti-TNF biologics was 6.9
units lower of FACIT-F score
or 8.19 units of SF-36 vital-
ity
5682
(11 studies)
⊕⊕⊕⊕
Moderatea
An SMD of 0.46 would be
considered as a moderate
ef fect. This equates to a
dif ference of 6.9 units (95%
CI 5.85 to 7.95) of FACIT-
F score (range 0-52) or 8.
19 units (95% CI 6.94 to 9.
43) of SF-36 vitality (range
0-100). NNTB 5 (95% CI 4 to
6)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; NNTB: number needed to treat for an addit ional benef icial outcome; SM D: standardised mean dif ference.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aThe quality of the studies were downgraded f rom high to moderate because of potent ial report ing bias (studies included
post hoc analysis favouring report ing of posit ive result and studies did not always include all randomised individuals.
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B A C K G R O U N D
Description of the condition
Rheumatoid arthritis (RA) is an autoimmune, systemic, inflam-
matory condition causing pain and synovitis in the joints of the
hands and feet (Conaghan 1999). Repeated flares of disease ac-
tivity cause symptoms of pain, fatigue, stiffness and loss of func-
tion. People with RA have identified fatigue as a key problem,
which they consider harder to manage than pain (Hewlett 2005).
Quantitative studies consistently show that significant fatigue oc-
curs in up to 70% of patients in the UK (almost 0.4 million peo-
ple) and is as common and severe as pain (Department of Health
2006; Wolfe 1996). There is a Cochrane review on the effect of
non-pharmaceutical interventions on fatigue in patients with RA
(Cramp 2013).
Description of the intervention
Medication for controlling the inflammatory response (and there-
fore symptoms) in RA comprises non-steroidal anti-inflamma-
tory drugs (NSAIDs), rapid introduction of disease-modifying
anti-rheumatic drugs (DMARDs), glucocorticoids and biologic
therapies to inhibit disease progression (Luqmani 2006). Al-
though there is evidence that biologic interventions can improve
symptoms of pain, stiffness, inflammation and loss of function
(Blumenauer 2002; Blumenauer 2003; Maxwell 2009; Mertens
2009; Navarro-Sarabia 2005; Singh 2009), and studies increas-
ingly include fatigue as a secondary outcome, no systematic re-
view has clearly established the evidence for improvement in RA
fatigue. Other pharmacological interventions such as anti-depres-
sants are often also used to improve intractable symptoms of RA
such as pain and may also improve fatigue. A separate review is
analysing these agents, along with DMARDs and NSAIDs.
How the intervention might work
RA fatigue probably acts through multiple and complex pathways
that vary between and within patients over time (Hewlett 2008).
Inflammatory activity may directly cause fatigue through systemic
effects or indirectly through its effects on pain and function (
Pollard 2006). Therefore, biologic agents may improve RA fatigue
by reducing the inflammatory components of fatigue, pain and
function.
Why it is important to do this review
People with RA have clearly identified fatigue as a common, un-
manageable symptom that reduces quality of life (Hewlett 2005),
and there is international consensus that all clinical trials should
measure it (Kirwan 2007). In addition, ongoing research identifies
fatigue as a key symptom associated with disease flare. Although
there is no systematic review on the evidence for the effect of phar-
macological interventions on RA fatigue, investigators often re-
port the symptom as a secondary outcome. Clinicians need to be
able to evaluate the potential (or limitations) of such interventions
for reducing RA fatigue in order to reach concordant decisions
with patients on treatment options.
O B J E C T I V E S
To evaluate the effect of biologic interventions on fatigue in
rheumatoid arthritis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Inclusion criteria
Randomised controlled trials of biologics in adults with confirmed
RA that included fatigue as a primary or secondary outcome mea-
sure (and not just an adverse effect) and reported it separately for
RA participants (Arnett 1988).
Exclusion criteria
Studies that only investigated non-biologic interventions or non-
pharmacological interventions.
Types of participants
Adults (usually over 18 years of age) with a diagnosis of RA ei-
ther confirmed by rheumatologist or using American College of
Rheumatology (ACR) criteria (Arnett 1988).
Types of interventions
All recognised biologic interventions. These included anti-TNF
(infliximab, etanercept, adalimumab, certolizumab pegol and goli-
mumab) and non-anti-TNF (rituximab, abatacept, tocilizumab,
anakinra, canakinumab and anti-IFN gamma monoclonal anti-
body) biologic agents.
The comparison arm could have been a placebo, alternative inter-
vention (pharmacological or non-pharmacological) or usual care,
including no specific intervention for fatigue.
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Types of outcome measures
Primary outcomes
The primary outcomes for this systematic review were change in
self reported fatigue scores using validated measures and adverse
events.Wedefined validatedmeasures as instruments used to assess
fatigue in clinical trials or observational studies as detailed in a
recent review (Hewlett 2007). We included adverse events in the
initial protocol; however, since then a separate Cochrane review
has assessed adverse events associatedwith anti-TNFandnon-anti-
TNF biologic treatments, so we have referred to this publication
rather than conducting a separate analysis (Singh 2011).
Secondary outcomes
In addition to presenting data on the primary outcome of fatigue
in the ’Summary of findings’ table, we also extracted the secondary
outcomes of pain, anxiety and depression.
Search methods for identification of studies
We developed our search strategies in line with recommendations
from the Cochrane Musculoskeletal Review Group and present
them in Appendix 1. We applied these search strategies to all
databases, adapting them appropriately to suit database style.
Electronic searches
We searched the following electronic databases.
• Cochrane Central Register of Controlled Trials
(CENTRAL) (2014, Issue no).
• MEDLINE (1966 to April 2014).
• EMBASE (1983 to April 2014).
• Cochrane Database of Systematic Reviews (2007 to April
2014).
• Current Controlled Trials Register (USA) (2000 to April
2014).
• The National Research Register (NRR) Archive (UK)
(2006 to April 2014).
• The UKCRN Portfolio Database (UK) (2006 to April
2014).
• AMED (1985 to April 2014).
• CINAHL (1982 to April 2014).
• PsycINFO (1974 to April 2014).
• Social Science Citation Index (1990 to April 2014).
• Web of Science (1990 to April 2014).
• Dissertation Abstracts International (1871 to April 2014).
• WHO International Clinical Trials Registry Platform
(ICTRP) (Nov 2005 to April 2014).
Searching other resources
In addition, we handsearched the reference lists of included studies
and previous review papers to find additional studies, as well as
the Topical Review Series on fatigue in musculoskeletal disease
(Hewlett 2008). We contacted relevant authors in the field to ask
about unpublished research that the search strategies could not
have detected.
Data collection and analysis
Selection of studies
Two review authors assessed titles and abstracts for all records iden-
tified through the search strategies, retrieving full texts for all those
that appeared to meet the inclusion criteria. We also acquired the
full reports if there was any uncertainty or disagreement surround-
ing their inclusion, or if abstracts were not available and it was not
possible to exclude the trial on title alone. Two independent review
authors screened all full-text articles for inclusion/exclusion crite-
ria, resolving disagreements by discussion and the involvement of
an arbiter where necessary.
Data extraction and management
For data extraction, the review team allocated papers to different
authors according to their areas of expertise, and two reviewers
independently retrieved the following details for each publication,
tabulating them on a standardised form: intervention (including
characteristics and duration); details of the participants’ health sta-
tus; assignment to groups (including process used, concealment
and comparability of groups); outcome measures; details of out-
comemeasures used for assessing fatigue, timing of measurements;
adherence to intervention/control, sample size and statistical anal-
ysis methods (including use of intention-to-treat principle) as well
as power to detect a change in fatigue, adverse events and with-
drawals.
Assessment of risk of bias in included studies
The two review authors independently assessed the methodolog-
ical quality of each trial using individual components of quality
from tools such as the one provided by Cochrane. Additionally,
two independent review authors assessed the risk of bias of the
included studies. As recommended in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2008), we assessed the
following methodological domains.
1. Sequence generation.
2. Allocation concealment.
3. Blinding of participants, personnel and outcome assessors.
4. Incomplete outcome data.
5. Selective outcome reporting.
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6. Other potential threats to validity (e.g. appropriate use of
co-interventions).
We explicitly assessed each of these domains as being at ’low’ or
’high’ risk of bias; where insufficient information was available,
or there was uncertainty over the potential for bias, we rated the
study as being at ’unclear’ risk of bias in that domain.
We also assessed the power of the study to detect change in RA
fatigue by examining the power calculations reported in the stud-
ies. Where this was missing, we based our assessment on recent
publications focusing on the Patient Acceptable Symptom State or
theminimally important differences in RA fatigue (Heiberg 2008;
Wells 2007). We also used methods described in (Hewlett 2007)
to assess the validity of the fatigue measure.
Measures of treatment effect
As we expected, the identified studies used a range of fatigue out-
come measures, so we calculated standardised mean differences
(SMD). We recorded the central estimate (mean) and standard
deviation (SD). Where the standard deviations were not explicitly
stated, we calculated them from the standard error, the different
means and their respective confidence intervals (CIs) or P values.
Where studies described adverse events as dichotomous data, we
had planned to report them as the proportion of participants ex-
periencing the event in each arm and would have made compar-
isons using the risk ratio (RR) and the corresponding 95% CI.
For rare events (< 10%), we planned to report the Peto odds ratio.
However, as stated in Primary outcomes, in the end we did not
perform any analyses on adverse events since this has already been
studied in a separate Cochrane review (Singh 2011).
Unit of analysis issues
Some studies included multiple doses of the same intervention.
In these cases, we divided the control group into equal numbers
and included pairwise comparisons in the meta-analysis as recom-
mended in sections 9.3.9 and 16.5.4 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2008).
Dealing with missing data
Where the change in scores was not available, we sought these data
from the authors. Failing that, we imputed them using methods
recommended in section 16.1.3.2 of Higgins 2008.
We carried out an intention-to-treat analysis in studies that in-
cluded participants allocated to the intervention arm regardless of
whether or not they completed the follow-up. In these studies we
assumed that participants who dropped out of the study had no
changes in their outcomes, assigning a conservative assessment of
response to treatment. We requested further details from authors
in cases where published data were incomplete.
Assessment of heterogeneity
Where appropriate, we formally assessed heterogeneity of the data
using the I2 statistic (Higgins 2003). We judged a value greater
than 50% to represent substantial heterogeneity. Where we de-
tected this level of heterogeneity and there were sufficient studies
available, we conducted subgroup analyses in an attempt to ex-
plain the heterogeneity.
Assessment of reporting biases
We used a funnel plot to assess the possibility of publication bias.
Data synthesis
We evaluated the quality of included studies using the GRADE
approach (Schünemann 2008), which employs the following rat-
ing system: randomised trials (high), downgraded randomised tri-
als (moderate), double-downgraded randomised trials (low) and
triple-downgraded randomised trials (very low). The quality rat-
ings may be decreased by:
1. limitations in the design and implementation of available
studies, suggesting a high likelihood of bias;
2. indirectness of evidence (indirect population, intervention,
control, outcomes);
3. unexplained heterogeneity or inconsistency of results
(including problems with subgroup analyses);
4. imprecision of results (wide confidence intervals); or
5. high probability of publication bias.
We expected a mixture of changes from baseline and absolute
group differences across a variety of measures of RA fatigue. We
also anticipated some variation in methods of analysis, includ-
ing absolute difference compared between groups, and baseline-
adjusted differences between groups. We followed the Cochrane
guidelines described in section 9.4.5.2 of Higgins 2008 to decide
which group of studies we could include in any meta-analysis. We
imputed the SD if necessary as described in section 16.1.3.
Summary of finding tables
We present the grading and meta-analyses in a ’Summary of find-
ings’ table.
Where there was no heterogeneity, we used a fixed-effect model,
and where there was heterogeneity, we used a random-effects
model. When the outcome used, or the number, quality or het-
erogeneity of existing trials contraindicated meta-analysis, we re-
ported and discussed each study individually, using effect sizes
for fatigue difference (differences divided by the SD) and Cohen’s
statistic (0.2 to 0.5 = small effect, 0.5 to 0.8 = moderate, > 0.8 =
large effect) (Cohen 1998). We calculated SMDs for pooled data
in meta-analysis. If trials reported more than one outcome mea-
sure, such as FACIT and SF-36 VT, we used the latter. Negative
values indicated reduction in the fatigue.
In order to estimate the number needed to treat for an additional
beneficial outcome (NNTB) from the SMD, we performed a log
transformation of the SMD to an odds ratio (OR) (Chinn 2000).
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Subsequently, we combined the resulting OR with an assumed
control event rate (CER = 0.5) generating an estimated NNTB.
These control group risks refer to proportions of people who im-
proved by some (unspecified) amount in the continuous outcome
(’responders’).
Subgroup analysis and investigation of heterogeneity
Where sufficient studies were available and the data were heteroge-
nous, we carried out separate meta-analyses for studies according
to different biologic agents.
Sensitivity analysis
We planned the following sensitivity analyses a priori in order to
explore differences in effect size and to assess whether the conclu-
sions were robust to the decision-making process.
1. The effect of risk of bias in included studies - defined as
adequate allocation concealment and blinding of outcome
assessors.
2. The effect of imputing missing data or transforming
variables.
R E S U L T S
Description of studies
Results of the search
Weundertook a comprehensive literature search, including screen-
ing of titles and abstracts (where available). We retrieved 54 full-
text references for further evaluation, including 32 that met the
criteria for the current review and excluding the remaining 22.
Handsearching of reference lists led to the retrieval of six further
full-text studies; we excluded one because fatigue was not an out-
comemeasure and five because we were unable to obtain necessary
data from the authors (Figure 1).
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Figure 1. Study flow diagram
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Included studies
All the studies recruited participants with established RA who
fulfilled ACR criteria (Arnett 1988). There were 20 studies of
five anti-TNF agents: one studied infliximab (Maini 1999), three
studied etanercept (Bae 2013; Emery 2008; Moreland 1999),
six studied adalimumab (Hørslev-Petersen 2014; Keystone 2004;
Mittendorf 2007; Soubrier 2009; Strand 2012b;Weinblatt 2003),
five studied certolizumab pegol (Choy 2012; Fleischmann 2009;
Pope 2012; Smolen 2009a; Strand 2009), and five studied goli-
mumab (Emery 2009; Keystone 2009; Li 2013; Smolen 2009b;
Weinblatt 2013). All but two were randomised placebo-controlled
trials: Mittendorf 2007 reported the result of a pooled analysis of
six randomised placebo-controlled trials of adalimumab in RA,
while Bae 2013 was a randomised open-label active comparator
trial of etanercept. Of the 12 non-anti-TNF biologic studies, 4
studied abatacept (Genovese 2005; Kremer 2003; Kremer 2006;
Schiff 2008), three studied rituximab (Cohen 2006; Emery 2006;
Rigby 2011), three studied tocilizumab (Genovese 2008; Smolen
2008; Strand 2012a), one studied canakinumab (Alten 2011), and
one was an early phase trial of an anti-IFN gamma monoclonal
antibody (Lukina 1998). All but two of these studies were ran-
domised placebo-controlled trials: Bae 2013 compared etanercept
with standard DMARD, and Lukina 1998 (which was translated
fromRussian) compared the effect of anti-interferon gamma (anti-
IFNγ ) monoclonal antibody with anti-TNF antibodies as well as
a combination of anti-IFNγ and anti-TNF antibodies. The sam-
ple size of Lukina 1998 was not based on statistical estimation;
the study only recruited 25 participants and allocated just five to
each treatment arm. This study (Lukina 1998) and the study by
Maini 1999 did not contribute data to the meta-analysis as we
were unable to obtain precise estimate including standard devia-
tion of change from the authors. In some trials, both active partic-
ipants and controls could receive concomitant DMARDs. These
studies added either biologics or placebo to DMARDs. The dose
of the latter did not change from baseline. In total, these studies
included 9,946 participants in the intervention groups and 4,682
participants in the control groups.
The primary outcomes of the included studies were disease activ-
ity, mostly assessed by ACR response criteria. The only exception
is the pooled analyses in Mittendorf 2007, which focused on pa-
tient-reported outcomes. None of the studies used fatigue as their
primary outcome. These studies used five different instruments to
assess fatigue: the Functional Assessment of Chronic Illness Ther-
apy Fatigue Domain (FACIT-F), Short Form-36 Vitality Domain
(SF-36 VT), visual analogue scale (VAS) (0 to 100 or 0 to 10)
and the Numerical Rating Scale NRS (0 to 10). The most com-
monly used instrument was SF-36 VT, which authors reported in
15 studies. Nine studies used the FACIT-F, five used a VAS, and
three used an NRS. Fatigue measures were taken at the primary
endpoints, which for most trials were at 24 weeks or less. One
trial assessed fatigue at six weeks (Pope 2012), two trials at three
months (Genovese 2005; Kremer 2003), and two studies at week
52 (Keystone 2004; Kremer 2006). Most papers did not provide
data on pain, anxiety or depression, hence we were unable to con-
duct analyses of these secondary outcomes.
Excluded studies
Twenty-two excluded publications did not meet the review in-
clusion criteria for the following reasons: 8 were not randomised
controlled trials (Cella 2005; Duggan 2009; Frampton 2007;
Kavanaugh 2012; Sansonno 2003; Strand 2012; Strand 2014;
Yount 2007), 12 did not report fatigue as an outcome mea-
sure (Breedveld 2005; Furst 2003; Genovese 2010; Grigor 2004;
Haugeberg 2009; Moreland 2000; Moreland 2002; Kavanaugh
2003; Kim 2007; Kremer 2008; Song 2007; Tak 2008), and two
papers were conference abstracts superseded by another publica-
tion (Dougados 2007; Gnanasakthy 2013). We report details of
the excluded studies in the Characteristics of excluded studies ta-
bles.Of the additional six studies identified through reference lists,
five studies are awaiting classification until enough data is avail-
able to make a decision regarding inclusion (Elliott 1994; Kosinski
2000; St Clair 2004; Van der Kooij 2009; Westhovens 2006). We
excluded the one remaining study, as fatigue was not an outcome
measure andwas a duplicate of a previously excluded study (Grigor
2004).
Risk of bias in included studies
Overall, for most of the included studies the risk of bias was low
or unclear (Figure 2). However, for Lukina 1998, an early phase II
trial of anti-IFNγ monoclonal antibody, the risk of bias was high.
This study did not provide any precision estimates on fatigue, so
we did not include its results in the meta-analyses of this review.
Authors of study byMaini 1999 didnot provide standard deviation
so data from the study were not included in the meta-analysis. Li
2013 and Pope 2012 were only available as conference abstracts, so
carried a potential high risk of bias since details on randomisation,
allocation concealment, blinding were not reported. Therefore,
details on method of allocation, blinding and completeness of
reporting could not be assessed adequately.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Investigators described all the studies as randomised controlled
trials but did not report themethodof randomisation in 12 studies.
Blinding
Investigators described all but two studies as double-blind,
placebo-controlled trials (Lukina 1998; Bae 2013); however, 10
studies do not provide details.
Incomplete outcome data
Four studies did not provide sufficient details on attrition (Bae
2013; Li 2013; Lukina 1998; Pope 2012), and four studies did
not account for a number of the participants who dropped out
before the end of the studies (Emery 2006; Kremer 2003; Kremer
2006; Smolen 2009b).
Selective reporting
Selective reporting bias was a concern in four studies that either
did not report details of improvement in fatigue or health-related
quality of life (HRQol) or did not report them at the primary
endpoint of the trial (Emery 2008; Fleischmann 2009; Keystone
2004; Soubrier 2009) . Four studies described patient-reported
outcomes from previously published RCTs (Bae 2013; Strand
2009; Strand 2012a; Strand 2014).
Other potential sources of bias
In four studies, the lack of information on completeness of data
from the questionnaire was a potential risk of bias (Emery 2006;
Emery 2008, Lukina 1998; Maini 1999). Maini 1999 reported
the second year result of a randomised controlled trial. After the
first year, 94 participants had a treatment gap of over eight weeks,
while the rest continued immediately into the second year. Those
participants with the gap may have received other medications.
Furthermore standard deviations of change were not provided by
the authors. Lukina 1998 had no placebo control arm and had a
very short-term follow-up as well as a very small sample size. Fur-
thermore, authors did not provide the statistical analysis method
or precision estimates. A funnel plot of all the studies did not sug-
gest significant publication bias (Figure 3).
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Figure 3. Funnel plot of comparison: 1 All Biologics, outcome: 1.1 All studies - fatigue continuous measures.
Effects of interventions
See: Summary of findings for themain comparisonAll biologics
for fatigue in rheumatoid arthritis
Some of the trials were multidose trials and therefore provided
at least two comparisons for the purpose of meta-analyses. Data
fromLukina 1998 andMaini 1999 did not contribute to the result
of the meta-analyses because the trial did not provide precision
estimates, and there was no placebo control group. All the ran-
domised placebo-controlled trials reported statistically significant
improvement in disease activity as well as pain score in the active
treatment groups when compared with controls. Two studies did
not use placebo controls (Bae 2013; Lukina 1998).
Primary outcomes
Self reported fatigue
Overall treatment by biologic agents led to a statistically signifi-
cant reduction in fatigue with an SMD of−0.43 (95% CI−0.49
to−0.38; P < 0.00001; Analysis 1.1; Figure 4). There was statisti-
cally significant heterogeneity (I2 = 48%, P < 0.0001). Anti-TNF
biologic agents had an SMD of−0.42 (95% CI−0.49 to−0.35,
P < 0.00001; Analysis 2.1; Figure 5) and non-anti-TNF agents
had an SMD of −0.46 (95% CI −0.53 to −0.39; P < 0.00001;
Analysis 4; Figure 5), showing similar effects on fatigue (Summary
of findings for the main comparison). However, there was statis-
tically significant heterogeneity in anti-TNF trials (I2 = 54%, P =
0.0002). The precise cause of heterogeneity is unclear but may be
due to different dosage, participant characteristics (early versus es-
tablished disease), previous treatment (biologic naive versus failed
biologic participants) and comorbidities that are associated with
fatigue (e.g. depression).
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Figure 4. Forest plot of comparison: 1 All Biologics, outcome: 1.1 All studies - fatigue continuous measures.
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Figure 5. Forest plot of comparison: 4 Subgroup comparison: anti-TNF vs non anti-TNF, outcome: 4.1 Anti-
TNF and non anti-TNF - fatigue continuous measures.
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We performed sensitivity analyses to explore the potential cause(s)
of heterogeneity. Excluding dose-ranging studies or trials in partic-
ipants who had failed previous biologic therapy did not affect het-
erogeneity.Disease durationwas, however, a significant factor. Five
studies assessed the effect of anti-TNF agents in early rheumatoid
arthritis (Emery 2008; Hørslev-Petersen 2014; Moreland 1999;
Soubrier 2009; Strand 2012b). Excluding these studies reduced
heterogeneity to statistical insignificance in the anti-TNF meta-
analysis (I2 = 30%, P = 0.08). Most of the studies also reported
significant improvement in disease activity as measured by ACR
response criteria, disease activity score or both.
Secondary outcomes
Five studies did not report results of pain score, tender and swollen
joints, or depression (Emery 2006; Kremer 2006; Maini 1999;
Mittendorf 2007; Schiff 2008). All the other studies reported sta-
tistically significant reduction in pain score, physical function, and
tender and swollen joint counts. However, improvement in pain
was reported but data were not provided in many papers. Dif-
ferent pain instruments were used, visual analogue scale, SF-36
bodily pain, numeric rating scale and percentage of patients with
improvement in pain. Consequently, we were unable to pool data
on pain for meta-analysis. Most of the studies did not assess anxi-
ety or depression. We could not determine whether reduction in
fatigue is due to reduction in disease activity, pain, depression or
a combination of these.
D I S C U S S I O N
Summary of main results
The aim of this review was to provide an overview of the effects
of biologic interventions on fatigue in people with RA. The re-
view revealed 32 RCTs investigating biologic interventions and
including fatigue as an outcome measure. There were two main
categories of biologic interventions: anti-TNF (20 studies) and
non-anti-TNF biologics (12 studies). Overall the quality of the
evidence was moderate. Both anti-TNF and non-anti-TNF bio-
logic treatments led to a small to moderate reduction in fatigue in
participants with RA.
Overall completeness and applicability of
evidence
Randomised controlled trials of biologic agents for RA commonly
assess fatigue. Clinical trials included in this review included all
current biologic agents licensed for the treatment of RA. Themag-
nitude of improvement is similar in the included studies.However,
most of the studies were phase III trials conducted for the purpose
of registration. Consequently, participants recruited into these tri-
als had high disease activity, and the primary outcome measure
was improvement in disease activity; change in fatigue was a sec-
ondary outcome measure. As the primary purpose of the inter-
ventions was not fatigue reduction, no consideration was given to
factors that may confound or explain it, such as depression and
reduced haemoglobin. Moreover, it is unclear whether improve-
ment in fatigue was due to a reduction in overall disease activity or
due to specific actions of the biologic agent. Analysis of fatigue in
these studies did not make any adjustment for possible confound-
ing factors such as change in pain, haemoglobin or mood. The
duration of most of the double-blind randomised controlled trials
was 24 weeks or less. It is unclear whether improvement in fa-
tigue is sustained with long-term therapy. In these trials, recruited
participants had highly active disease and moderate to high levels
of fatigue at baseline. It is unclear whether biologic interventions
improve fatigue in patients with moderate or low level of fatigue.
Quality of the evidence
Almost all the studies included are double-blind, randomised
placebo-controlled trials. The quality of these trials was moder-
ate, with highly variable reporting of fatigue using different mea-
surement instruments. The SF-36 VT was the most commonly
used instrument. Many of these instruments were not developed
specifically for assessing fatigue in RA, although they have been
validated for assessing fatigue in other medical conditions and in
general health. The use of the SF-36 VT may also be question-
able, as vitality may not be at the opposite end of the spectrum
to fatigue. Consistent use of outcomes would simplify pooling of
data and allow comparison between interventions.
Potential biases in the review process
There are two trials for which we failed to obtain data on fatigue
from the authors; therefore there is some risk of reporting bias.
Agreements and disagreements with other
studies or reviews
A recently published systematic review suggested that the biologic
agents have a small to moderate effect in improving fatigue in
RA, although it only included 10 studies (Chauffier 2012), all of
which are included in this review. By including more studies, this
Cochrane review reduces the risk of publication bias.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Treatment with biologic interventions in patients with active RA
and moderate to high levels of fatigue may lead to a small to mod-
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erate improvement in fatigue. The magnitude of improvement is
similar for anti-TNF and non-anti-TNF biologic agents. How-
ever, it is unclear whether the improvement results directly from
the biologic interventions on fatigue or indirectly through reduc-
tion in inflammation and disease activity.
Implications for research
Future research needs to determine the mechanisms whereby bi-
ologic interventions reduce fatigue in patients with RA, in par-
ticular, to assess whether this is a direct or indirect effect of bio-
logic agents through intermediary factors such as disease activity.
In addition, it is important to assess whether the improvement in
fatigue associated with biologic interventions observed in short-
term randomised controlled trials is maintained in the long term.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alten 2011
Methods RCT of 12 weeks
Participants Outpatient clinics, Multicentre international
Males or females ≥ 18 years of age
Revised 1987 ACR classification criteria for RA, symptoms for ≥ 3 months
Active RA, defined as≥ 6/28 tender and swollen joints withCRP≥ 10mg/L, erythrocyte
sedimentation ≥ 28 mm or both
ACR Functional status classes I, II, or III
Treated with methotrexate at the maximum tolerated dose (≤ 25 mg/week) and at a
stable dose of ≥ 7.5 mg/week for ≥ 12 weeks.
Patients who had failed treatment with any DMARD, including any such agent used in
combination with methotrexate as well as any biologic agent, were eligible for participa-
tion after an appropriate washout period.
Systemic corticosteroids, NSAIDs, including cyclooxygenase-2 inhibitors or paraceta-
mol, had to have been stable doses for at least 4 weeks. Maximum allowable dose of
systemic corticosteroids was ≤ 10 mg/day prednisone or an equivalent for ≥ 4 weeks
Group 1-4:
Percentage Female: 81.2%, 89.1%, 84.5% and 74.3% respectively
Age, mean (SD) years: 57.10 (11.899), 61.02 (12.244), 55.62 (11.236), 57.53 (12.121)
respectively
Exclusion
Previous hypersensitivity to the study drug or to molecules with similar structures
Intra-articular therapy for RA within the previous 4 weeks
Pregnant or breastfeeding
Positive TB skin test without a follow-up negative chest X-ray
Interventions Group 1: canakinumab 150 mg subcutaneously (SC) every 4 weeks + MTX
Group 2: canakinumab 300 mg SC every 2 weeks + MTX
Group 3: canakinumab 600 mg IV loading dose followed by 300 mg SC every 2 weeks
+ MTX
Group 4: Placebo subcutaneously every 2 weeks + MTX
Outcomes Primary outcome: response to treatment according to ACR 50 criteria at 12 weeks
Secondary outcomes:
• Responses according to ACR 20 and ACR 70 at week 12
• ACR 20, ACR 50, and ACR 70 responses at any visit
• ACR component variables
• Short Form-36 (SF-36); Functional Assessment of Chronic Illness Therapy-
Fatigue (FACIT-F); Disease Activity Score 28 (DAS 28, as well as DAS-based EULAR
criteria; and Health Assessment Questionnaire (HAQ) at week 12
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Alten 2011 (Continued)
Exclusions Previous hypersensitivity to the study drug or to molecules with similar structures
Intra-articular therapy for RA within the previous 4 weeks
Pregnant or breastfeeding
Positive TB skin test without a follow-up negative chest X-ray
Fatigue outcomes FACIT, 0-52, high = good
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised in a double-blind fashion
Allocation concealment (selection bias) Unclear risk Randomised in a double-blind fashion
Blinding (performance bias and detection
bias)
All outcomes
Low risk Randomised in a double-blind fashion
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT
Selective reporting (reporting bias) Low risk Fatigue was reported in the main study report
Bae 2013
Methods RCT of 16 weeks
Participants Outpatient clinics
Multicentre, Hong Kong, India, Malaysia, Philippines, Taiwan, Korea and Thailand
RA, based on 1987 ACR criteria
28-joint Disease Activity Score [DAS28] ≥3.2, who displayed inadequate response to
oral MTX (stable dosing between 7.5 mg/week and 25 mg/week for minimum 3months
ETN + MTX group: 91.4% female, mean age (± SD) 48.4 years ± 12.0
DMARD+MTX group: 88.4% female, mean age (± SD) 48.5 years ± 11.3,
Exclusion
Not stated
Interventions Subcutaneous etanercept (ETN) 25 mg per injection twice weekly was added to
methotrexate (MTX)
MTX according to local use, orally, weekly mean dose was 12.9 mg (1.9 mg-25 mg)
Patients were randomized to either of two treatment groups in an approximate 2:1 ratio:
1. ETN+MTX (N= 197) or
2. DMARD +MTX (N= 103).
DMARD therapy (defined as the addition of DMARD investigator’s choice to MTX)
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Bae 2013 (Continued)
followed the standard of care and approved local label or recommendations; the three
most frequently used DMARDs in the study were leflunomide (n = 69), sulfasalazine (n
= 23) and hydroxychloroquine (n = 11)
Outcomes Primary Outcome: ACR response
Secondary Outcomes
1. Health Assessment Questionnaire (HAQ) ranges 0 (best) - 3 (worse)
2. SF-36 in eight domains: bodily pain, general health, physical functioning, role-phys-
ical, mental health, role-emotional, social functioning and vitality. SF-36 scores range
from 0 (worst) to 100 (best) for each of the eight domains.
3. Hospital Anxiety and Depression Scale (HADS) ranges 0 (best) to 3 (worst)
4. FACIT-F Scale. Scores range from 0 to 52, with higher scores indicating less fatigue
5. Work Productivity and Activity Impairment Questionnaire: General Health (WPAI:
GH) measures percentage impairment of usual activities and percentage impairment of
work and productivity due to health, with higher scores reflecting higher percentage
impairment
All assessments were carried out at baseline, week 8 and 16
Exclusions Not stated
Fatigue outcomes Fatigue Assessment Scale (FAS) NRS, 0-10, high = bad, SF-36 vitality
Notes This is patient-reported outcome paper, earlier paper reported the main study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported in the text
Allocation concealment (selection bias) High risk Open-label
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
High risk SD are not reported
Selective reporting (reporting bias) High risk This is patient-reported outcome paper, earlier paper reported
the main study
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Choy 2012
Methods RCT of 24 weeks
Participants Outpatient clinic, Multicentre international
Inclusion criteria
Aged 18-75 years
Adult-onset RA of at least 6 months as defined by the 1987 ACR criteria
Active disease defined as > 9 tender joints, > 9 swollen joints and at least 1 of the 3
following criteria: > 45 min EMS, ESR > 28 mm/h or CRP > 10 mg/L
Receiving MTX for at least 6 months and on a stable dosage of 15-25 mg/week for at
least 8 weeks (10-15 mg/week was deemed acceptable in cases where a dosage reduction
had been necessary because of toxicity).
All other DMARDs were to have been discontinued at least 28 days before the first study
medication dose
Exclusion
Any form of inflammatory arthritis other than RA
History of chronic, serious or life-threatening infection, current infection
History or chest X-ray suggestive of tuberculosis, or positive (defined per local medical
practice) purified protein derivative (PPD) skin test (Mantoux)
History of infected joint prosthesis
IM, IV or IA CSs or IA hyaluronic acid in the 4 weeks preceding the study
Prior treatment with any TNF- inhibitor
Receipt of any experimental, unregistered or biological therapy in the 6months preceding
the study
NSAIDs and oral CSs at a dosage of < 10 mg/day prednisone equivalent were allowed if
stable for > 4 weeks before study entry and thereafter
Analgesics not allowed during the 4 days preceding baseline assessment, except parac-
etamol, which was not allowed within 24 h
Group 1 and 2:
Gender (percentage female): 72.2% and 66.1% respectively
Age, mean (S.D.), years 53.0 (12.3) and 55.6 (11.7) respectively
Interventions SC reconstituted lyophilised CZP 400 mg or placebo every 4 weeks from baseline to
week 20
MTX 15-25 mg/week (10-15 mg/week was allowed if the dose had been reduced because
of toxicity)
Group 1: CZP + MTX
Group 2: Placebo + MTX
Outcomes Primary outcome: ACR 20 response rate at week 24
Secondary outcomes:
• ACR 50 and ACR 70 response rates, together with ACR core component
measures:
◦ Tender/painful joint count (TJC) (68 joints graded 0-3)
◦ Swollen joint count (SJC) (66 joints graded 0-3)
• Pain (100-mm VAS)
• Patient’s and physician’s global assessments of arthritis (5-point categorical Likert
scale)
• HAQ-Disability Index (0-3)
• SF-36 (0-100)
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Assessments of endpoints at weeks 1, 2, 4, 8, 12, 16, 20, 22 and 24
Exclusions Any form of inflammatory arthritis other than RA
History of chronic, serious or life-threatening infection, current infection
History or chest X-ray suggestive of tuberculosis, or positive (defined per local medical
practice) purified protein derivative (PPD) skin test (Mantoux)
History of infected joint prosthesis
IM, IV or IA CSs or IA hyaluronic acid in the 4 weeks preceding the study
Prior treatment with any TNF- inhibitor
Receipt of any experimental, unregistered or biological therapy in the 6months preceding
the study
NSAIDs and oral CSs at a dosage of < 10 mg/day prednisone equivalent were allowed if
stable for > 4 weeks before study entry and thereafter
Analgesics not allowed during the 4 days preceding baseline assessment, except parac-
etamol, which was not allowed within 24 h
Fatigue outcomes SF-36, 0-100, high = good
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were randomised on a 1:1 basis via an interactive voice-
response system
Allocation concealment (selection bias) Low risk Patients were randomised on a 1:1 basis via an interactive voice-
response system
Blinding (performance bias and detection
bias)
All outcomes
Low risk To preserve the blind to clinical research staff, the study site
pharmacist labelled clinical supplies (study medication syringes)
, and a sorbitol placebo was used to match the viscosity of CZP.
Placebo injections
Incomplete outcome data (attrition bias)
All outcomes
Low risk Efficacy evaluations were carried out in the modified intention-
to-treat (mITT) population, defined as all randomised patients
who had taken at least 1 dose of study medication.
For continuous data, missing data were imputed by last obser-
vation carried forward (LOCF) analysis
Selective reporting (reporting bias) Low risk Fatigue was reported in the main study report
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Methods RCT of 24 weeks, followed up until week 104 weeks
Participants Outpatient clinic, multicentre international
Inclusion
18-80 years, active RA (≥ 8 swollen or tender joints), RA minimum 6 months, non-
response to anti-TNF, taking MTX for minimum 12 weeks prior to screening
Exclusion
Significant systemic involvement secondary to RA, ACR functional class IV
Group 1 and 2:
Gender (percentage female): 81% and 81% respecitively
Age (mean (SD) years): 52.8 (12.6), 52.2 (12.2) respecitively
Interventions Rituximab 1000 mg on days 1 and 15 or placebo
MTX (10-25 mg/week orally or parenterally), folate (≥ 5 mg/week),
IV methylprednisolone (100 mg 30 min before infusion) and oral prednisolone (60 mg
on days 2-7, 30 mg on days 8-14)
Group 1: Placebo + MTX
Group 2: RTX + MTX
Outcomes Primary outcome: ACR 20 response at week 24
Secondary outcomes:
• Pain VAS at baseline and week 24
• HAQ disability index at baseline and week 24
• DAS at baseline and week 24
• SF-36 at baseline and week 24
• Patient’s global assessment of disease activity at baseline and week 24
• Joint counts at baseline and week 24
• Blood tests
• Radiographs at baseline, 24, week 54, and 104
• Routine lab tests including ESR and CRP, 4 weekly
Exclusions Significant systemic involvement secondary to RA, ACR functional class IV
Fatigue outcomes FACIT-F, range 0-52, high = bad
SF-36 VT, 0-100, high = good
Notes Keystone 2008 provided further data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomised at a ratio of 3:
2”
Allocation concealment (selection bias) Low risk “Patients were randomised at a ratio of 3:
2”
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Blinding (performance bias and detection
bias)
All outcomes
Low risk “Blinded study with the study sponsor,
investigators and patients unaware of the
treatment assignment of each patient”
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT population was defined as all ran-
domised patients who received any part of
an infusion of study medication and in-
cluded patients who withdrew prematurely
from the study for any reason and forwhom
assessments were not made. Last observa-
tion carried forward
Selective reporting (reporting bias) Low risk Fatigue was reported in the main study re-
port
Emery 2006
Methods 3 x 3 factorial RCT of 24 weeks
Participants Outpatient clinic, Multicentre international
Inclusions
18-80 years, active RA (≥ 8 swollen or tender joints/CRP ≥ 1.5 mg/dL or ESR ≥
28mm/h) despite MTX. Failed 1-5 DMARDS or biologic agents, glucocorticoids ≤ 10
mg/day, RF positive
Exclusions
Significant systemic RA, other illness or lab abnormalities, recurrent significant infec-
tions, prior rituximab, allergy to agents
Gender
Placebo (percentage female): 80% (placebo), 83% (RTX 2x500mg) and 80% (RTX
2x1000mg)
Age (mean years): 51.1 (placebo) 51.4 (RTX 2x500mg) and 51.1 (RTX 2x1000mg)
Interventions All patients received MTX (10-25 mg/week); no other DMARDs were permitted
RTX IV infusion on day 1 and 15.
9 Groups
1. RTX 2 x 500 mg + placebo glucocorticoid on days 1 and 15
2. RTX 2 x 500 mg + 100 glucocorticoid on day 1 and 15
3. RTX 2 x 500 mg + IV methylprednisolone premedication + oral prednisone for 2
weeks
4. RTX 2 x 1000 mg + placebo glucocorticoid on days 1 and 15
5. RTX 2 x 1000 mg + 100 glucocorticoid on days 1 and 15
6. RTX 2 x 1000 mg + intravenous methylprednisolone premedication + oral prednisone
for 2 weeks
7. Pacebo 2 x infusion + placebo glucocorticoid on days 1 and 15
8. Placebo 2 x infusion + 100 glucocorticoid on days 1 and 15
9. Placebo 2 x infusion + intravenous methylprednisolone premedication + oral pred-
nisone for 2 weeks
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Outcomes Primary outcome: ACR 20 at 24 week
Secondary outcomes:
ACR50, 70
EULAR response
HAQ-DI
SF-36
FACIT-F
safety
All assessments at baseline and week 24
Exclusions Significant systemic RA, other illness or lab abnormalities, recurrent significant infec-
tions, prior rituximab, allergy to agents
Fatigue outcomes FACIT-F, range 0-52, high = good
SF-36 VT, high = good
Notes Fatigue was reported in the main study report
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised control trial
Allocation concealment (selection bias) Low risk “Double-blind, double-dummy”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double-blind, double-dummy”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropouts “failed”
Selective reporting (reporting bias) Low risk Fatigue was reported in the main study report
Emery 2008
Methods RCT of 52 weeks
Participants Outpatient clinics
Multicentre, international in Europe, Latin America, Asia, and Australia
Inclusions
18 years or older, diagnosis of adult-onset rheumatoid arthritis, disease duration mini-
mum 3 months maximum 2 years, DAS 28 of 3.2 or more, and either Westergren ESR
of ≥ 28 mm/h or CRP of ≥ 20 mg/L
Exclusions
Previous treatment with MTX, etanercept, or another TNF antagonist at any time or
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treatmentwith otherDMARDs or corticosteroid injections in the 4weeks before baseline
visits. Individuals with important concurrent medical diseases were ineligible, as were
those with other relevant comorbidities
Group 1 and 2:
Gender (percentage female): 73% and 74% respecitively
Age (mean (SD) years): 52.3 (0.8), 50.5 (0.9) respecitively
Interventions All participants received oral methotrexate, starting at 7.5 mg once a week
ETN 50mg by subcutaneous injection once a week for 52 weeks. In patients with tender
or swollen joints, the dose was titrated up over 8 weeks to a maximum of 20 mg a week
Group 1: Placebo+ MTX
Group 2: ETN + MTX
Outcomes Primary outcomes:
• Proportion of patients achieving remission (DAS 28 < 2.6) at week 52
• Change in van der Heijde modified total Sharp score at week 52
Secondary outcomes (at weeks 12, 24, 36 and 52):
• Functional status (HAQ), employment questionnaire
• PRO measures: included the HAQ, EuroQoL health status, pain, HADS (EQ-
5D) and visual analogue scale (VAS) (EQ-5D VAS), pain VAS, HADS
• employment questionnaire
Exclusions Previous treatment with MTX, etanercept, or another TNF antagonist at any time or
treatmentwith otherDMARDs or corticosteroid injections in the 4weeks before baseline
visits. Individuals with important concurrent medical diseases were ineligible, as were
those with other relevant comorbidities
Fatigue outcomes Fatigue VAS, 0-100, high = bad
SF-36 VT, 0-100, high = good
Notes For all patients stable doses of oral corticosteroids (≤ 10 mg per day of prednisone or
an equivalent agent) or a single non-steroidal anti-inflammatory drug were permitted
if started at least 4 weeks before baseline and kept constant throughout the first 24
weeks of the study. After completion of 24 weeks of treatment, reductions in dose of
prednisone or other oral corticosteroid by 1 mg per day or less were allowed every week.
Oral corticosteroids were tapered to 3 mg per day or less before the dose of non-steroidal
anti-inflammatory drug was decreased. All patients received folic acid supplementation
of 5 mg twice weekly (not given on the same day as methotrexate) to reduce side effects
associated with methotrexate
Fatigue data reported in Kekow 2010.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned with a computerised ran-
domisation and enrolment (CORE) system to generate and im-
plement allocation sequence, manage assignment to treatment
groups, and maintain blinding
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Allocation concealment (selection bias) Low risk Participants were randomly assigned with a computerised ran-
domisation and enrolment (CORE) system to generate and im-
plement allocation sequence, manage assignment to treatment
groups, and maintain blinding
Blinding (performance bias and detection
bias)
All outcomes
Low risk Data were unblinded only if needed for medical management
of patients. Masking was removed for one sponsor biostatistical
programmer to do the 52-week primary analysis for this report
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT/LOCF
Selective reporting (reporting bias) High risk results of employment questionnaire were not reported
Emery 2009
Methods RCT of 24 week
Participants Outpatient clinic, Multicentre international
Inclusions
Adults who had RA, according to ACR criteria for at least 3 months
Had not received more than 3 weekly doses of oral MTX as treatment of RA
Active RA, with at least 4 swollen joints and at least 4 tender joints AND at least 2 of
the following
• CRP level of > 1.5 mg/dL or ESR of > 28 mm/h
• Norning stiffness lasting 30 min or longer
• Bone erosion by radiography, MRI or both
• Anti-CCP or RA positivity
Prespecified TB screening criteria. Patients with positive results for TB skin or whole
blood interferon-γ -based QuantiFERON-TB testing could participate but had to start
prophylaxis for latent TB before or simultaneously with administration of the first dose
of the study agent.
Concurrent use of NSAIDs, other analgesics for RA, and oral corticosteroids (< 10 mg
of prednisone/day or equivalent) was allowed if doses were stable for > 2 weeks
Patients receiving anakinra could participate 4 weeks after receiving the last dose
Patients receiving alefacept or efalizumab could participate 3 months after receiving the
last dose
Patients receiving an experimental agent could participate after the equivalent of 5 half-
lives of the agent
Exclusions
Patients who had previously received infliximab, etanercept, adalimumab, rituximab,
natalizumab or cytotoxic agents, including chlorambucil, cyclophosphamide, nitrogen
mustard, and other alkylating agents, were excluded
Group 1, 2 3, and 4
Gender (percentage female): 83.8%, 84.3%, 84.9% and 78.6% respectively
Age, mean (SD) years: 48.6 (12.91), 48.2 (12.85), 50.9 (11.32) and 50.6 (11.58)
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Interventions Golimumab subcutaneously at week 0 and then every 4 weeks
MTX started at 10 mg/week at week 0 and escalated by 2.5 mg every 2 weeks to 20 mg/
week by week 8
Duration of intervention = 24 weeks reported here (but 52 weeks plus 5 years open label
extension)
Group 1: placebo by SC injection plus MTX
Group 2: golimumab 100 mg by SC injection plus placebo capsules
Group 3: golimumab 50 mg by SC injection plus MTX capsules
Group 4: golimumab 100 mg by SC injection plus MTX capsules
Outcomes Primary outcome: difference in the ACR 50 response at week 24 between groups 3 and
4 combined (combined group) versus group 1 and a pairwise comparison (group 3 or
group 4 versus group 1).
Secondary outcomes:
• ACR 20, ACR 70 and ACR 90 responses
• Numeric index of the ACR response (ACR-N)
• DAS 28 (both versions of the DAS 28 composite score, i.e., using the CRP or the
ESR, were used to determine the DAS 28 response)
• HAQ
• Changes in haemoglobin levels in patients with baseline anaemia
Exclusions Patients who had previously received infliximab, etanercept, adalimumab, rituximab,
natalizumab or cytotoxic agents, including chlorambucil, cyclophosphamide, nitrogen
mustard, and other alkylating agents, were excluded
Fatigue outcomes SF-36 VT. 0-100, high = good
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk An interactive voice response system (IVRS) was used to ran-
domly assign eligible patients to 1 of 4 treatment groups in ap-
proximately equal proportions
Allocation concealment (selection bias) Low risk IVRS was used to randomly assign eligible patients to 1 of 4
treatment groups in approximately equal proportions
Blinding (performance bias and detection
bias)
All outcomes
Low risk Golimumab and placebo were supplied as sterile liquid (aque-
ous medium of histidine, sorbitol, and polysorbate 80 (pH 5.
5) with or without golimumab) for SC injection. Active and
placeboMTXwere supplied as double-blinded, identical opaque
capsules (filled with microcrystalline cellulose with or without
MTX). An independent assessor at each study centre, who had
no access to patient records and no other role in the study, per-
formed the joint assessments
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Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised patients (all of those who were entered in the
IVRS for randomisation regardless of receipt of study treatment)
were analysed by assigned treatment group (ITT) approach. Pa-
tients for whom all week 24 (the primary end point visit) ACR
component data were missing were considered non-responders,
as were patients meeting predefined treatment failure criteria re-
lated to prohibited concomitant medications or discontinuation
of the SC study agent due to lack of efficacy. Actual week 24
data were used for patients who discontinued the study agent
for reasons other than lack of efficacy but returned for clinical
evaluations, but these patients were considered non-responders
if they met any of the treatment failure criteria
Selective reporting (reporting bias) Unclear risk Main paper, methods section does not say whether fatigue and
SF-36 data are collected, but these are presented in a later paper
Fleischmann 2009
Methods RCT of 24 weeks
Participants Outpatient clinic, Multicentre international
Inclusion criteria
18-75 years, adult onset RA minimum 6 months, failed ≥1 DMARD, active disease ≥
9 (out of 68) tender joints and ≥ 9 (out
of 66) swollen joints and ≥ 1 of the following: > 45 min of morning stiffness, ESR ≥
28 mm/h, CRP > 10 mg/L
Exclusions
Any inflammatory arthritis other than RA, history of chronic, serious or life-threatening
infection, any current infection, history of or a chest x ray suggesting tuberculosis or a
positive PPDskin test, patientswho received biological therapies forRAwithin 6months,
prior treatment with TNF-α inhibitors, intra-articular, periarticular, intramuscular
and intravenous corticosteroids
Group 1 and 2
Gender (percentage female): 89%and 78.4% respectively
Age, mean (SD) years: 54.9 (11.6) and 52.7 (12.7) respectively
Interventions 400 mg SC certolizumab pegol
Group 1: Placebo SC
Group 2: Certolizumab pegol SC
Outcomes Primary outcome: ACR 20 response at 24 weeks
Secondary outcomes at week 24:
• ACR 50/ACR 70
• ACR component scores
• DAS (ESR)3
• HAQ-DI
• HRQoL
• SF-36
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• Pain VAS
• Brief Pain Inventory
• Safety
Exclusions Any inflammatory arthritis other than RA, history of chronic, serious or life-threatening
infection, any current infection, history of or a chest x ray suggesting tuberculosis or a
positive PPDskin test, patientswho received biological therapies forRAwithin 6months,
prior treatment with TNF-α inhibitors, intra-articular, periarticular, intramuscular
and intravenous corticosteroids
Fatigue outcomes SF-36 VT, 0-100, high = good
Fatigue Assessment Scale, 11-point scale, high = bad
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Interactive voice randomisation service
Allocation concealment (selection bias) Low risk Interactive voice randomisation service
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Intervention and placebo solutions were administered by
blinded study personnel. No details given about outcome asses-
sors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Modified ITT for all efficacy analyses
Selective reporting (reporting bias) High risk Health-related quality of life data not shown but improvements
claimed. SF-36 data not published but have been provided sub-
sequently
Genovese 2005
Methods RCT of 6 months
Participants Outpatient clinic, Multicentre international
Inclusion criteria
At least 10 swollen/12 tender joints, RA ≥ 1 year, ≥ 18 years, inadequate response to
anti-TNF (etanercept, infliximab or both), CRP at least 1mg/dL, taking oral DMARD/
anakinra for 3vmonths stable for minimum 28 days. If steroids - stable for 28 days
Exclusions
Not stated
Group 1 and 2
Gender (percentage female): 77.1% and 79.9% respectively
Age, mean (SD) years: 53.4 (12.4) and 52.7 (11.3)respectively
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Interventions Abatacept 2:1 stratified for anti-TNF use prior to trial. 10 mg/kg body weight. IV
infusion days 1, 15, 29 then every 28 days to day 141 inclusive
Group 1: Abatacept IV infusion
Group 2: Placebo IV infusion
Outcomes SF-36, DAS, HAQ
Exclusions Not stated
Fatigue outcomes SF-36 VT, range 0-100, high = good
VAS, range 0-100, high = bad
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk RCT
Allocation concealment (selection bias) Unclear risk Insufficient details
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis
Selective reporting (reporting bias) Low risk Fatigue was reported in the main study report
Genovese 2008
Methods RCT of 24 weeks
Participants Outpatient clinic, Multicentre international
Inclusion criteria
> 18 years with moderate-to severe RA of > 6 months’ duration
Diagnosed according to the ACR criteria
Swollen joint count > 6, tender joint > 8, CRP > 1 mg/dL or ESR > 28 mm/h
Stable doses of permitted DMARDs (methotrexate, chloroquine, hydroxychloroquine,
parenteral gold, sulfasalazine, azathioprine, leflunomide) for > 8 weeks prior to study
entry
Oral glucocorticoids (< 10 mg/day prednisone or equivalent) and NSAIDs permitted if
the doses were stable for > 6 weeks
Exclusions
Patients who were unsuccessfully treated with an anti-TNF agent or were previously
38Biologic interventions for fatigue in rheumatoid arthritis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Genovese 2008 (Continued)
treated with any cell-depleting therapy
Group 1 and 2
Gender (percentage female): 81% and 84% respectively
Age, mean (SD) years: 53 (13) and 54 (13)
Interventions Tocilizumab at a dose of 8 mg/kg intravenously as a 60 min infusion every 4 weeks,
combined with stable DMARD therapy Duration of intervention was 24 weeks with
doses at 0, 4, 8, 12, 16, 20, 24 weeks
Group 1: Tocilizumab IV infusion + DMARDs
Group 2: Placebo IV infusion + DMARDs
Outcomes Primary outcome: proportion of patients who had achieved a response according to ACR
20 at week 24
Secondary outcomes at week 24:
• Proportion of patients with ACR 50/70
• Time to onset of ACR 20/50/70 responses
• DAS 28
• EULAR
• Haemoglobin levels
• HAQ
Exclusions Patients who were unsuccessfully treated with an anti-TNF agent or were previously
treated with any cell-depleting therapy
Fatigue outcomes SF-36 VT, range 0-100, high = good
FACIT-F, 0-52, high = good
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, double-blind, placebo-controlled, international,
multicentre
Allocation concealment (selection bias) Unclear risk Randomised, double-blind, placebo-controlled, international,
multicentre
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind RCT, drugs administered in blinded fashion
Patients were assessed using a dual-assessor approach for efficacy
and safety evaluations, to ensure that blinding was not compro-
mised
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analysis was by ITT. All patients who received at least 1 injection
with adalimumab or placebo were included. LOCF was applied
for patients who withdrew from the trial before the 12-month
visit. In a post hoc analysis, non-responder imputation (NRI) of
the patients who withdrew from the study was performed for the
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primary outcome. ITT analysis without LOCF and completers’
analysis were also performed and gave similar results (not shown)
Selective reporting (reporting bias) Low risk Fatigue was reported in the main study publication
Hørslev-Petersen 2014
Methods RCT of 12 months
Participants Outpatient clinic, Multicentre Denmark
Inclusion criteria
Patients (≥ 18 years) with RA according to the ACR classification criteria who have had
the diagnose < 6 months
Moderate to severe rheumatoid arthritis defined as DAS 28 (CRP-based) > 3.2.
Negative pregnancy test (serum HCG) for women of childbearing potential prior to
trial start. (Non-fertile women are defined as postmenopausal for at least 1 year or
surgical sterilisation (bilateral tubal ligation, bilateral oophorectomy or hysterectomy)
. Fertile women included in the trial should use contraception during the entire trial
period (i.e. one of the following methods: oral contraception, intrauterine device (IUD)
, depot injection of progesterone, subdermal implantation, contraceptive vaginal ring,
transdermal depot plaster). In addition, contraception should be used for a period of
150 days after any discontinuation of trial medicine.
Ability and willingness to inject the SC injections alone or to have an assistant give the
injections
Ability and willingness to give written informed consent and to meet the requirements
of the trial protocol
Exclusions
People with latent TB defined with a positive Mantoux test (> 12 mm for vaccinated
and 6 mm for non-vaccinated), positive cultivation of mycobacteria in tissue samples,
chest X-ray indicating TB,or other risk factors for activation of untreated latent TB,
and people not been given adequate TB prophylaxis according to the instructions of the
department
Active or recurrent infections or severe infections requiring hospitalisation or treatment
with IV antibiotics within the last 30 days or oral antibiotics within the last 14 days prior
to inclusion
Positive serology for hepatitis B or C indicating active infection
Medical history with a positive HIV status (check of HIV test upon suspicion)
Medical history with histoplasmosis or listeriosis
Previous cancer or lymph proliferative disease except cases treated radically and have
been without relapse for a minimum of 5 years. Patients with previous squamous cell
carcinoma, basal cell skin carcinoma or cervical dysplasia, who have been treated suc-
cessfully and radically can be included
Previous diagnosis or signs of demyelinised disease in the central nervous system (e.g.
optic neuritis, visual disorder, disturbed gait, facial paralysis, apraxia)
Severe renal insufficiency (creatinine clearance < 35 mL/min - nomogram)
Affected liver function: liver enzymes > 2 x above normal limit value
Clinically significant drug or alcohol abuse during the past year or current daily alcohol
consumption
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Unstable diabetes, unstable ischaemic heart disease, heart insufficiency (NYHA III-
IV), active chronic inflammatory intestinal disease, recent cerebral apoplexia (within 3
months), chronic leg ulcer or any other condition (e.g. kateter a demeure), which ac-
cording to the investigator imposes an increased risk to the participant
Anticoagulant therapy
Pregnancy or breastfeeding
Other inflammatory rheumatic diseases
Aggressive parvovirus B19 infection
Previous treatment with one or more DMARDs
Glucocorticosteroid treatment within the last 4 weeks (except nasal and inhalation
steroids)
Contraindications for trial medicine
Group 1 and 2
Gender (percentage female): 63% and 69% respectively
Age, mean (range) years: 56.2 (25.8-77.6) and 54.2 (28.3-76.7) respectively
Interventions Group 1: Adalimumab SC + MTX
Group 2: Placebo SC + MTX
Adalimumab group: adalimumab 40 mg subcutaneously every second week
Both groups:
started oral methotrexate, 7.5 mg/week at baseline, increased to 15 mg/week after 1
month and 20 mg/week after 2 months (or the highest tolerated dose) in combination
Any swollen joint observed at baseline or at a subsequent visit was injected with triam-
cinolone hexacetonide (40 mg/mL, 0.5-2 mL/joint). Up to 4 joints (max. 4 mL) could
be injected per visit.
If unacceptable disease activity persisted at the 3 months’ visit or thereafter, that is, either
DAS 28CRP≥ 3.2 +≥ 1 swollen joint or intra-articular injection of 4mL triamcinolone
had been given monthly for 3 consecutive months, then hydroxychloroquine (200 mg/
day) and sulphasalazine (2 g/day) were added. If the treatment target (lowdisease activity)
was not achieved within an additional 3 months, adalimumab/placebo-adalimumab was
discontinued, the patient was considered a non-responder and excluded from the study,
and open-label biologics (other than adalimumab) were prescribed at the discretion of
the treating physician
Outcomes Primary outcome: proportion of patients in each group that had achieved low disease
activity (DAS 28, CRP < 3.2) at 12 months
Secondary outcomes (at 12 months):
• DAS 28 CRP
• The proportions of patients who achieved: DAS 28 remission (DAS 28 CRP < 2.
6)
• Clinical Disease Activity Index (CDAI) remission (CDAI ≤ 2.8)
• Simplified Disease Activity Index (SDAI) remission (SDAI < 3.3)
• ACR/EULAR 28/40 Boolean remission
• Absence of disability measured by HAQ and SF-12v2 physical component score
(PCS)
• Quality of life (EQ-5D)
• SF12-mental component score
• Patient-reported outcomes (HAQ, VAS for pain, fatigue and global, SF12 and
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EQ-5D)
The doctor recorded number of swollen and tender joints (N = 40), doctor’s global score
(VAS)
Exclusions People with latent TB defined with a positive Mantoux test (> 12 mm for vaccinated
and 6 mm for non-vaccinated), positive cultivation of mycobacteria in tissue samples,
chest X-ray indicating TB,or other risk factors for activation of untreated latent TB,
and people not been given adequate TB prophylaxis according to the instructions of the
department
Active or recurrent infections or severe infections requiring hospitalisation or treatment
with IV antibiotics within the last 30 days or oral antibiotics within the last 14 days prior
to inclusion
Positive serology for hepatitis B or C indicating active infection
Medical history with a positive HIV status (check of HIV test upon suspicion)
Medical history with histoplasmosis or listeriosis
Previous cancer or lymph proliferative disease except cases treated radically and have
been without relapse for a minimum of 5 years. Patients with previous squamous cell
carcinoma, basal cell skin carcinoma or cervical dysplasia, who have been treated suc-
cessfully and radically can be included
Previous diagnosis or signs of demyelinised disease in the central nervous system (e.g.
optic neuritis, visual disorder, disturbed gait, facial paralysis, apraxia)
Severe renal insufficiency (creatinine clearance < 35 mL/min - nomogram)
Affected liver function: liver enzymes > 2 x above normal limit value
Clinically significant drug or alcohol abuse during the past year or current daily alcohol
consumption
Unstable diabetes, unstable ischaemic heart disease, heart insufficiency (NYHA III-
IV), active chronic inflammatory intestinal disease, recent cerebral apoplexia (within 3
months), chronic leg ulcer or any other condition (e.g. kateter a demeure), which ac-
cording to the investigator imposes an increased risk to the participant
Anticoagulant therapy
Pregnancy or breastfeeding
Other inflammatory rheumatic diseases
Aggressive parvovirus B19 infection
Previous treatment with one or more DMARDs
Glucocorticosteroid treatment within the last 4 weeks (except nasal and inhalation
steroids)
Contraindications for trial medicine
Fatigue outcomes VAS (visual analog scale), range 0-100 mm, high = bad
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomised in blocks of 4 from a central, com-
puter-generated list of study numbers
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Hørslev-Petersen 2014 (Continued)
Allocation concealment (selection bias) Low risk Patients were randomised in blocks of four from a central, com-
puter-generated list of study numbers
Blinding (performance bias and detection
bias)
All outcomes
Low risk Randomised, double-blind, placebo-controlled, 2-armed, paral-
lel-group, multicentre trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analysis was by ITT. All patients who received at least 1 injection
with adalimumab or placebo were included. LOCF was applied
for patients who withdrew from the trial before the 12-month
visit. In a post hoc analysis, non-responder imputation (NRI) of
the patients who withdrew from the study was performed for the
primary outcome. ITT analysis without LOCF and completers’
analysis were also performed and gave similar results (not shown)
Selective reporting (reporting bias) Low risk Fatigue was reported in the main study publication
Keystone 2004
Methods RCT of 52 weeks
Participants Outpatient clinic, Multicentre international
Inclusion criteria
≥18 years of age or older, active RA diagnosed (Arnett 1988), ≥ 9 tender joints, ≥
6 swollen joints, a CRP concentration over 1 mg/dL, and either rheumatoid factor
positivity or ≥ 1 joint erosion on radiographs of the hands and feet. Must have been on
MTX therapy for ≥ 3 months at a stable dose of 12.5-25 mg/week (or ≥ 10 mg/week
in patients intolerant to MTX) for ≥ 4 weeks
Group 1, 2 3, and 4
Gender (percentage female): 83.8%, 84.3%, 84.9% and 78.6% respectively
Age, mean (SD) years: 48.6 (12.91), 48.2 (12.85), 50.9 (11.32) and 50.6 (11.58)
Exclusions
Prior use of anti-CD4 antibody therapy or TNF antagonists, a history of an active in-
flammatory arthritide other than RA, a history of active listeriosis or mycobacterial in-
fection, a history of lymphoma, leukaemia or other malignancy besides non-melanoma
skin cancer within 5 years, a major episode of infection (i.e. infections requiring hospi-
talisation, treatment with intravenous antibiotics within 30 days prior to screening, or
oral antibiotics within 14 days prior to screening), any uncontrolled medical condition,
and pregnancy or breastfeeding
Groups 1, 2 and 3
Gender (percentage female): 76.3%, 75.5% and 73% respectively
Age mean (SD) years: 56.1 (13.5), 57.3 (10.5) and 56.1 (12.0) respectively
Interventions Ad40: single self injections (1.6 mL/injection) of adalimumab subcutaneously at 40 mg
every other week (with placebo injections on alternate weeks)
Ad20: adalimumab subcutaneously at 20 mg every week
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Traditional DMARDs other than MTX were discontinued at least 28 days prior to
the study baseline. Oral corticosteroids, if used previously, were allowed at a maximum
prednisone-dose equivalent of 10 mg/day.
At week 16 or thereafter, patients who were not achieving an ACR 20 response (im-
provements of at least 20% in the ACR core criteria) were allowed to receive rescue treat-
ment with a traditional DMARD at the discretion of their treating physician. Patients
commencing other therapies after not achieving an ACR 20 response were considered
treatment failures for the purposes of clinical efficacy (determined by the ACR score for
level of improvement) from that time onward. Patients who received rescue therapy and
continued in the study were included in the radiographic analysis
Group 1: Ad40 SC + MTX
Group 2: Ad20 SC + MTX
Group 3: Placebo SC + MTX
Outcomes Primary outcomes: ACR 20 response at week 24
Secondary outcomes:
• Posteroanterior radiographs of the hands/wrists and anteroposterior radiographs
of the feet
• ACR 20, ACR 50, ACR70 - joint counts, global assess of pain/disease activity
• Disability index of the HAQ
• Health-related quality of life was assessed at baseline and at weeks 12, 24, and 52
using the SF-36
• Safety was assessed through recording of adverse events, physical examinations,
and standard laboratory tests
Exclusions Prior use of anti-CD4 antibody therapy or TNF antagonists, a history of an active in-
flammatory arthritide other than RA, a history of active listeriosis or mycobacterial in-
fection, a history of lymphoma, leukaemia or other malignancy besides non-melanoma
skin cancer within 5 years, a major episode of infection (i.e. infections requiring hospi-
talisation, treatment with intravenous antibiotics within 30 days prior to screening, or
oral antibiotics within 14 days prior to screening), any uncontrolled medical condition,
and pregnancy or breastfeeding
Fatigue outcomes SF-36 VT, range 0-100, high = good
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “[R]andomly assigned” but no details
Allocation concealment (selection bias) Unclear risk “[R]andomly assigned” but no details
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of personnel not stated, placebo injection given to par-
ticipants at identical times, X-ray scorers “blinded to the treat-
ment, chronologic order and clinical response of each patient”
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Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT, LOCF
Selective reporting (reporting bias) High risk Primary endpoint 24weeks but fatigue only reported at 52weeks
Keystone 2009
Methods RCT of 52 weeks
Participants Outpatient clinic, Multicentre international (Argentina, Australia, Canada, Chile, Ger-
many, Hungary, Mexico, New Zealand, Poland, South Korea, Taiwan and the USA.)
Inclusion criteria
Swollen joint count > 6, tender joint > 8, CRP > 1 mg/dL or ESR > 28 mm/h
≥ 18 years of age
RA according to the revised 1987 ACR criteria for least 3 months
Active RA, despite previous MTX therapy, which was defined as≥ 4 swollen joints (out
of 66 total) and ≥ 4 tender joints (of 68) and at least 2 of the following: screening CRP
of at least 1.5 mg/dL or ESR of at least 28 mm, morning stiffness of at least 30 min,
bone erosion as observed by radiograph or MRI, positive for anti-CCP or RF
Patients must have received a stable dose of MTX (≥ 15 mg/week but not > 25 mg/
week) during the 4-week period immediately preceding screening and to have tolerated
a dose ≥ 15 mg/week for at least 3 months
Eligible patients had to have met the tuberculosis screening criteria.
Patients who were using NSAIDs or other analgesics for RA had to be taking a stable
dose for at least 2 weeks before the first dose of study agent. Patients who were taking
oral corticosteroids had to have been receiving a stable dose equivalent to 10 mg/day or
less of prednisone for ≥ 2 weeks before the first dose of study agent
Group 1, 2 3, and 4
Gender (percentage female): 83.8%, 84.3%, 84.9% and 78.6% respectively
Age, mean (SD) years: 48.6 (12.91), 48.2 (12.85), 50.9 (11.32) and 50.6 (11.58) re-
spectively
Interventions Group 1: placebo SC + MTX
Group 2: golimumab 100 mg by SC injection plus placebo capsules
Group 3: golimumab 50 mg by SC injection plus MTX capsules
Group 4: golimumab 100 mg by SC injection plus MTX capsules
MTX was at participants’ pre-study stable dose
Outcomes Primary outcomes:
• ACR 20 at week 14
• HAQ at week 24
Secondary outcomes at week 14 and 24:
• DAS 28
• ACR 50 and 70
• SF-36
• FACIT-F
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Exclusions Hypersensitivity to human immunoglobulin proteins or other components of goli-
mumab. Any previous use of any anti-TNF agent, rituximab, natalizumab or cytotoxic
agents. Should not have received anakinra; disease-modifying antirheumatic drugs other
than methotrexate; intravenous, intramuscular or intra-articular corticosteroids within
4 weeks before the first dose of study agent; or alefacept or efalizumab within 3 months
before the first dose of the study agent
Fatigue outcomes FACIT-F, 0-52, high = good
Notes GO FORWARD - FACIT data (replaces original data extraction on Keystone 2009
which had been supplemented by data from authors, this is now the full paper)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisationwas stratified by investigational site andwas con-
ducted using a telephone IVRS
Allocation concealment (selection bias) Low risk Randomisationwas stratified by investigational site andwas con-
ducted using a telephone IVRS
Blinding (performance bias and detection
bias)
All outcomes
Low risk Packaging identical, independent assessor used
Golimumab and placebo were supplied as sterile liquid for SC
injection. Placebo injections contained the same solution as ac-
tive golimumab but did not contain the monoclonal antibody.
Active methotrexate and placebo methotrexate were supplied as
identical opaque capsules. Injections were administered every 4
weeks and each patient received 2 injections per dose (0.5 mL
and 1.0 mL syringes) to maintain the blind.
An independent assessor designated at each study centre per-
formed all joint assessments. The joint assessor had no other
contact with the patient, was not the treating physician and
was not permitted to review patient medical records, case report
forms, or previous joint counts during the study
Incomplete outcome data (attrition bias)
All outcomes
Low risk All analyses were based on an ITT principle, and all statistical
testing was performed 2-sided at a significance level of 0.05. An
LOCF procedure was used for imputation of missing data and
for patients who entered the early escape procedure
Selective reporting (reporting bias) Unclear risk GOFORWARD - FACIT data (replaces original data extraction
on Keystone 2009 which had been supplemented by data from
authors, this is now the full paper)
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Kremer 2003
Methods RCT of 6 months
Participants Outpatient clinic, Multicentre international
Inclusion criteria
ACR criteria for RA, functional class I, II, III; MTX ≥ 6 months, stable for 28 days, no
other DMARDS in last 28 days, ≥ 10 swollen/12 tender joints, CRP ≥ 1mg/dL
Exclusions
Nursing/pregnant women
Group 1, 2 and 3
Gender (percentage female): 66%, 63% and 75% respectively
Age, mean (range) years: 54.7 (23-80), 54.4 (23-80) and 55.8 (17-83) respectively
Interventions CTLA4Ig infusions intravenously over 30 min period on days 1, 15, 30 and monthly
thereafter for total of 6 months. 2 groups: 10 mg/kg and 2 mg/kg. All groups including
controls received methotrexate
Group 1: Placebo IV infusion + MTX
Group 2: Abatacept 2mg/kg IV infusion + MTX
Group 3: Abatacept 10mg/kg IV infusion + MTX
Outcomes Primary outcome: ACR 20 at 6 months
Secondary outcomes at days 1, 15 and 30 and then monthly:
• HAQ
• Patient and physician global assessment of disease
• Patient assessment of pain
• CRP
• ACR 50, 70
• Blood tests including ESR and CRP
• SF-36
Exclusions Nursing/pregnant women
Fatigue outcomes SF-36 VT (0-100) high = good
Notes Vitality scale changed most out of all SF-36 dimensions
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A central randomisation procedure was used”
Allocation concealment (selection bias) Low risk “A central randomisation procedure was used”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind, outcome assessors unaware of patients’ treatment
assignments
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Kremer 2003 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk “To account for missing data in the assessment of the ACR
responses in
the primary, prespecified analysis, we considered patients who
discontinued the study because of worsening disease not to have
had a response, and we carried forward the values obtained at
the last assessment for patients who discontinued the study for
any other reason. Thus, all patients were assessed
for an ACR response.”
Selective reporting (reporting bias) Low risk Fatigue was reported in the main study publication
Kremer 2006
Methods RCT of 6 months
Participants Outpatient clinic, Multicentre international
Inclusion criteria
RA, functional class I, II, III; disease duration > 1 year, MTX ≥ 3 months, stable for
28 days, no other DMARDS in last 28 days, ≥ 10 swollen/12 tender joints, CRP ≥ 10
mg/L, ≤ 10 mg prednisolone/day over 25/28 days
Exclusions
None stated
Group 1 and 2
Gender (percentage female): 72.3%, and 70.2% respectively
Age, mean (SD) years: 51.5 (12.9) and 50.4 (11.58) respectively
Interventions Abatacept IV 10 mg/kg on days 1, 15, 29 and months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
= 14 doses. MTX ≥ 15 mg/week for 52 weeks
Group 1: Abatacept IV infusion + MTX
Group 2: Placebo IV infusion + MTX
Outcomes Primary outcome: ACR 20 response at 6 months
Seconday outcomes
• ACR50 and 70
• DAS28
• SF-36
• HAQ
• Genant-modified Sharp score
Exclusions None stated
Fatigue outcomes SF-36 VT, 0-100, high= good
VAS, 0-10, high = bad
Notes Important study showing reduction in fatigue but problems in obtaining data
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central by a drug company
Allocation concealment (selection bias) Low risk Central by a drug company
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patients were randomly assigned in a 2:1 ratio to receive either
a fixed
dose of abatacept, approximately 10 mg/kg of body weight, or
placebo
Incomplete outcome data (attrition bias)
All outcomes
High risk Not clear how many withdrew
Selective reporting (reporting bias) Low risk We performed all efficacy and safety analyses on a modified
intention-to-treat population, defined as all randomly assigned
patients who received at least 1 dose of study medication
Li 2013
Methods RCT of 1 year
Participants How and where patients were recruited were not reported
RA patients with active RA despite MTX
Baseline demographics and disease characteristics were generally similar between the
groups; median age was 49 yrs and 81.1% of patients were female
Interventions Group 1: Placebo SC every 4 week + MTX
Group 2: golimumab 50 mg every 4 weeks + MTX
Outcomes Primary outcome: ACR 20 at week 14
Secondary outcomes:
• DAS 28
• HAQ
• SF-36
• FACIT-F
Exclusions Not stated
Fatigue outcomes FACIT-F, range 0-52, high = good
Notes Abstract only
Risk of bias
Bias Authors’ judgement Support for judgement
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Li 2013 (Continued)
Random sequence generation (selection
bias)
Unclear risk not stated
Allocation concealment (selection bias) Unclear risk not stated
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk not stated
Selective reporting (reporting bias) Unclear risk not stated
Lukina 1998
Methods RCT of 6 months
Participants • Informed consent
• RA diagnosis according to ACR criteria
• Active disease
◦ Pain at least 25 mm on 100 mm VAS
◦ ≥ 6 swollen joints
◦ ≥ 8 tender joints
◦ At least 2 of the following 4 features
⋄ Morning stiffness 60 min or longer
⋄ Fatigue 50 mm or more on 100 mm VAS
⋄ ESR 25 mm/1st hour or higher
⋄ CRP 2.5 mg or higher
• No significant co-morbidities
• Stable dose of NSAIDs, corticosteroids or both ( ≤ 10 mg prednisolone per day)
for at least 1 month before inclusion in the study
• No effect of traditional DMARDs or impossibility to prescribe DMARDs or
refusal of DMARDs
• DMARDs stopped at least 3 months before inclusion in the study
Group 1, 2 3, and 4
Gender (percentage female): 83.8%, 84.3%, 84.9% and 78.6% respectively
Age, mean (SD) years: 48.6 (12.91), 48.2 (12.85), 50.9 (11.32) and 50.6 (11.58) re-
spectively
Interventions Group 1: anti-IFNα IM injection, 5 days, dose 96 mg at 1st injection and 144 mg at
days 2, 3, 4 and 5
Group 2: anti-IFNγ IM injection, 5 days, dose 96 mg at 1st injection and 144 mg at
days 2, 3, 4 and 5
Group 3: anti-TNF IM injection, 5 days, dose 96 mg at 1st injection and 144 mg at
days 2, 3, 4 and 5
Group 4: anti-IFNγ + anti-TNF IM injection, 5 days, dose 96 mg of each antibody at
days 1, 2, 3, 4 and 5
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Group 5: anti-IFNγ + anti-IFNα + anti-TNF IM injection, 5 days, dose 96 mg of each
antibody at days 1, 2, 3, 4 and 5
Outcomes • Pain VAS (100 mm)
• Morning stiffness
• Swollen joints count
• Tender joints count
• Grip strength (left and right hands)
• ESR
• CRP
• RF (latex test)
• Physician global assessment
Exclusions Pregnancy or breastfeeding
History of serum disease or any allergic reactions to protein preparations
Fatigue outcomes VAS, range 0-100 mm, high = bad
Notes Translator’s notes: I did not discuss the trial with the authors, but they do have expertise
in conducting trials, so I believe that true randomisation has been performed. The
authors stated that they collected clinical and laboratory data at multiple time points,
but only reported data on days 7 and 28; others were not reported. Also they stated that
patient global assessment has been performed - but no data reported. No baseline data
for outcomes were reported, only mean changes (without SDs)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “[R]andomised” but no details
Allocation concealment (selection bias) Unclear risk “[R]andomised” but no details
Blinding (performance bias and detection
bias)
All outcomes
High risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Not reported
Selective reporting (reporting bias) Unclear risk Possibly
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Maini 1999
Methods RCT of 54 weeks extended follow up to 104 weeks
Participants Outpatient clinic, Multicentre international
Inclusion criteria
Diagnosed with rheumatoid (1987 ACR criteria) and had evidence of active disease de-
spite treatment with methotrexate (≥ 6 swollen and tender joints plus 2 of the follow-
ing: morning stiffness greater than or equal to 45 min, erythrocyte sedimentation rate
greater than 28 mm/h, CRP greater than 2 mg/dL). The patients were classified into a
functional class (ACR criteria). Patients must also have been receiving oral or parenteral
methotrexate for at least 3 months with no break in treatment of more than 2 weeks
during this period. The methotrexate dose must have been stable at 12.5 mg/week or
more, for at least 4 weeks before screening and the patient must have been on a stable
dose of folic acid for the same period
Exclusions
Little or no ability for self care; any current inflammatory condition with signs and symp-
toms that might confound the diagnosis (e.g. connective tissue disease or Lyme disease);
used a DMARD other than methotrexate or received IA, IM or IV corticosteroids in the
4 weeks before screening; received any other agent to reduce TNF or had any previous
use of cyclophosphamide, nitrogen mustard, chlorambucil or other alkylating agents;
or a history of known allergies to murine proteins. Patients were also excluded if they
had had infected joint prosthesis during the previous 5 years; serious infections, such as
hepatitis, pneumonia, pyelonephritis in the previous 3 months; any chronic infectious
disease such as renal infection, chest infection with bronchiectasis or sinusitis; active tu-
berculosis requiring treatment within the previous 3 years; opportunistic infections such
as herpes zoster within the previous 2 months; any evidence of active cytomegalovirus;
active Pneumocystis carinii; or drug-resistant atypical mycobacterial infection. Other ex-
clusions: current signs or symptoms of severe, progressive, or uncontrolled renal, hep-
atic, haematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or
cerebral disease; a history of lymphoproliferative disease including lymphoma or signs
suggestive of disease, such as lymphadenopathy of unusual size or location (i.e. lymph
nodes in the posterior triangle of the neck, infraclavicular epitrochlear, or periaortic ar-
eas); splenomegaly; any known malignant disease except basal cell carcinoma currently
or in the past 5 years
All patients randomised
Gender (percentage female): 78%
Age, mean years: 54
Interventions All patients received intravenous infusions at the initiation of treatment (week 0) and
at weeks 2 and 6. 2 groups of patients were administered infliximab + MTX (1 group
receiving 3 mg/kg and the other receiving 10 mg/kg infliximab) and had subsequent
infusions every 4weeks, whereas 2 other groups of patients received infliximab plusMTX
(1 receiving 3 mg/kg and the other receiving 10 mg/kg infliximab) but had subsequent
infusions every 8 weeks, with placebo infusions at the interim 4-week visits
Group 1: Placebo IV infusion + MTX
Group 2: Infliximab 3mg/kg IV infusion every 8 weeks + MTX
Group 3: Infliximab 3mg/kg IV infusion every 4 weeks + MTX
Group 4: Infliximab 10mg/kg IV infusion every 8 weeks + MTX
Group 5: Infliximab 10 mg/kg IV infusion every 4 weeks + MTX
52Biologic interventions for fatigue in rheumatoid arthritis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Maini 1999 (Continued)
Outcomes Primary outcomes: ACR 20 at week 52
Secondary outcomes:
• Response to therapy included documentation of 50% and 70% improvement
• Reduction in individual measurements of disease activity
• HAQ
• SF-36
• modified Sharp/van der Heidje score
From Maini 2004 - HAQ, SF-36, sharp radiographic damage score, lab evaluations
Exclusions Little or no ability for self care; any current inflammatory condition with signs and symp-
toms that might confound the diagnosis (e.g. connective tissue disease or Lyme disease);
used a DMARD other than methotrexate or received IA, IM or IV corticosteroids in the
4 weeks before screening; received any other agent to reduce TNF or had any previous
use of cyclophosphamide, nitrogen mustard, chlorambucil or other alkylating agents;
or a history of known allergies to murine proteins. Patients were also excluded if they
had had infected joint prosthesis during the previous 5 years; serious infections, such as
hepatitis, pneumonia, pyelonephritis in the previous 3 months; any chronic infectious
disease such as renal infection, chest infection with bronchiectasis or sinusitis; active tu-
berculosis requiring treatment within the previous 3 years; opportunistic infections such
as herpes zoster within the previous 2 months; any evidence of active cytomegalovirus;
active Pneumocystis carinii; or drug-resistant atypical mycobacterial infection. Other ex-
clusions: current signs or symptoms of severe, progressive, or uncontrolled renal, hep-
atic, haematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or
cerebral disease; a history of lymphoproliferative disease including lymphoma or signs
suggestive of disease, such as lymphadenopathy of unusual size or location (i.e. lymph
nodes in the posterior triangle of the neck, infraclavicular epitrochlear, or periaortic ar-
eas); splenomegaly; any known malignant disease except basal cell carcinoma currently
or in the past 5 years
Fatigue outcomes SF-36 VT, Scale 0-100, high = good
Notes Fatigue data reported in Maini 2004
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “An independent organisation did the cen-
tralised randomisation”
Allocation concealment (selection bias) Low risk “An independent organisation did the cen-
tralised randomisation”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blinded
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Incomplete outcome data (attrition bias)
All outcomes
Low risk LOCF
Selective reporting (reporting bias) Unclear risk Maini 1999 does not mention HAQ/SF-
36 yet these were measured from baseline
and reported in Maini 2004
Mittendorf 2007
Methods A pooled analysis of 6 RCTs of at least 6 weeks and up to 6 months
Participants Outpatient clinic, Multicentre international
Inclusion criteria
RA
Exclusions
Pregnant/breastfeeding women, HIV positive, alcohol or drug abuse in previous 6
months, ongoing/active clinically relevant infection, major episode of infection requir-
ing hospitalisation or IV antibiotics in previous 30 days or oral antibiotics in previous
15 days; underlying cardiac, pulmonary, metabolic, renal, or gastrointestinal conditions,
chronic or latent infectious diseases, immune deficiency or abnormal laboratory values
All patients randomised
Gender (percentage female): 79.8%
Age, mean years (range): 54 (19-80)
Interventions Group 1: Adalimumab 40 mg every other week
Group 2: Placebo
Outcomes Clinical examination, disease activity, pain, HRQoL, SF-36, FACIT-F. No primary out-
come defined
Exclusions Pregnant/breastfeeding women, HIV positive, alcohol or drug abuse in previous 6
months, ongoing/active clinically relevant infection, major episode of infection requir-
ing hospitalisation or IV antibiotics in previous 30 days or oral antibiotics in previous
15 days; underlying cardiac, pulmonary, metabolic, renal, or gastrointestinal conditions,
chronic or latent infectious diseases, immune deficiency or abnormal laboratory values
Fatigue outcomes FACIT-F, range: 0-52, high = good
SF-36 VT, 0-100, high = good BUT data not available
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “[R]andomised” but no details
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Mittendorf 2007 (Continued)
Allocation concealment (selection bias) Unclear risk “[R]andomised” but no details
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT, LOCF
Selective reporting (reporting bias) High risk Pooled analysis
Moreland 1999
Methods RCT of 26 weeks
Participants Outpatient clinic, Multicentre North America
Inclusion criteria
Over 18 years, not wheelchair user, inadequate response to DMARD, ≥ 10 swollen
joints, ≥ 12 painful joints, ESR ≥ 28, CRP > 20 mg/L, EMS > 45 min
Exclusions
Patients on corticosteroid doses could not exceed the equivalent of
10 mg of prednisone per day
Group 1, 2 and 3
Gender (percentage female): 76%, 84%, and 74% respectively
Age, mean years: 51, 53, 50.9 and 53 respectively
Interventions Etanercept 10 mg or etanercept 25 mg twice weekly for 26 weeks
Group 1: Placebo SC
Group 2: Etanercept 10mg SC
Group 3: Etanercept 25mg SC
Outcomes Primary outcomes: 20% and 50% improvement in ACR responses at 3 and 6 months
Secondary outcomes:
• ACR 70
• Joint count
• General health
• HAQ
• Mental Health component of SF-36
Exclusions Patients on corticosteroid doses could not exceed the equivalent of
10 mg of prednisone per day
Fatigue outcomes HAQ VT (SF-36 VT scale) range 0-100, high = good
Notes -
Risk of bias
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Moreland 1999 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned, block randomisation stratified by study site,
codes housed by sponsor in locked database
Allocation concealment (selection bias) Low risk Randomly assigned, block randomisation stratified by study site,
codes housed by sponsor in locked database
Blinding (performance bias and detection
bias)
All outcomes
Low risk Placebo identical, outcome assessors had no knowledge of allo-
cation
Incomplete outcome data (attrition bias)
All outcomes
Low risk LOCF ITT
Selective reporting (reporting bias) Low risk Fatigue was reported in the main study publication
Pope 2012
Methods RCT of 12 weeks
Participants Outpatient clinic, multicentre international
Inclusion criteria
Active RA and inadequate response to at least 1 DMARD
Group 1, 2 3, and 4
Gender (percentage female): 83.8%, 84.3%, 84.9% and 78.6% respectively
Age, mean (SD) years: 48.6 (12.91), 48.2 (12.85), 50.9 (11.32) and 50.6 (11.58)
Exclusions
not stated
Gender and age not reported
Interventions Certolizumab (CZP) 400 mg at weeks 0, 2 and 4 followed by 200 mg every 2 weeks
added to current therapy
Group 1: CZP SC + DMARD
Group 2: placebo SC + DMARD
Outcomes • Sleep quantity and quality (Sleep Problem Index II domain of the Medical
Outcomes Study sleep scale)
• Pain (0-100 mm visual analogue scale)
• Patient’s global assessment of disease activity (0-100mm VAS)
Exclusions Not stated
Fatigue outcomes FACIT-F, range 0-52, high = good
Notes Abstract only
56Biologic interventions for fatigue in rheumatoid arthritis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pope 2012 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selective reporting (reporting bias) Unclear risk Not stated
Rigby 2011
Methods RCT of 52 weeks
Participants Outpatient clinic, Multicentre international
Inclusion criteria
Patients aged 18-80 years with a diagnosis of RA (> 8 weeks to < 4 years prior to baseline)
according to the revised 1987 ACR criteria
Group 1, 2 3, and 4
Gender (percentage female): 83.8%, 84.3%, 84.9% and 78.6% respectively
Age, mean (SD) years: 48.6 (12.91), 48.2 (12.85), 50.9 (11.32) and 50.6 (11.58)
Exclusions
not stated
Group 1, 2 and 3
Gender (percentage female): 77.1%, 81.5% and 84.8% respectively
Age, mean (SD) years: 48.1 (12.7), 47.9 (13.4) and 47.9 (13.3) respectively
Interventions Rituximab 500 mg on days 1 and 15 by IV; preceded by methylprednisolone 100 mg
MTX 7.5 mg/week titrated to 20 mg/week by week 8
Rituximab 1000 mg on days 1 and 15 by IV, preceded by methylprednisolone 100 mg;
MTX 7.5 mg/week titrated to 20 mg/week by week 8
Second course given at 24 weeks if DAS > 2.6 or later if it increased to that value
Group 1: Placebo + MTX
Group 2: Rituximab 500mg + MTX
Group 3: Rituximab 1000mg + MTX
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Outcomes Primary outcome: Radiographic damage by Genant score at week 52
Secondary outcomes at week 52:
• Functional disability measure (HAQ)
• Generic HRQOL measure (SF-36 version 2)
• Pain (VAS)
• Patient global assessment of disease activity
• FACIT-F
Exclusions None stated
Fatigue outcomes FACIT, 0-52, high = good
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation schedule, stratified by region (USA or rest of
world) and RF status (positive or negative), was generated by the
sponsor and supplied to an IVRS. At randomisation, patients
were assigned unique medication and randomisation numbers
via the IVRS
Allocation concealment (selection bias) Low risk The randomisation schedule, stratified by region (USA or rest of
world) and RF status (positive or negative), was generated by the
sponsor and supplied to an IVRS. At randomisation, patients
were assigned unique medication and randomisation numbers
via the IVRS
Blinding (performance bias and detection
bias)
All outcomes
High risk The sponsor, investigators and patients were blinded to treat-
ment allocation until week 52, at which time the sponsor was
unblinded for the purposes of data analysis (i.e. those undertak-
ing analysis were not blinded)
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT, LOCF
Selective reporting (reporting bias) Low risk Fatigue was reported in the main study publication
Schiff 2008
Methods RCT of 6 months
Participants Outpatient clinic, Multicentre international
Inclusion criteria
ACR criteria for RA. ≥ 18 years old, RA for ≥ 1 year, inadequate response to MTX.
Received at least 15 mg MTX per week for at least 3 months prior to randomisation,
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washed out all DMARDs except MT for 28 days
Exclusions
Prior experience of abatacept or anti-TNF therapy; TB
Group 1, 2 and 3
Gender (percentage female): 83.3%, 87.3%, and 82.4% respectively
Age, mean (SD) years: 49.0 (12.5), 49.4 (11.5) and 49.1 (12.0)
Interventions Abatacept: dosed according to weight: < 60 kg received 500 mg; 60-100kg received 750
mg; > 100kg received 1000 mg. IV infusion on days 1, 15 and 29 and every 28 days
thereafter up to and including day 337 (with normal saline received on day 43)
Infliximab: 3mg/kg, administered on days 1,15, 43 and 85 and every 56 days thereafter
(normal saline was received at the remaining visits)
Group 1: Abatacept IV + MTX
Group 2: Placebo IV + MTX
Group 3: Infliximab IV + MTX
Outcomes Primary outcome: disease activity (DAS 28) at day 197
Secondary outcomes at day 197:
• ACR 20, 50 and 70
• EULAR response
• HAQ-DI
• SF-36
• Safety
Exclusions Prior experience of abatacept or anti-TNF therapy; TB
Fatigue outcomes SF-36 VT, 0-100, high = good
Notes Author contacted to ask for vitality data at 6 months as this was the primary endpoint;
placebo participants were reassigned at 6 months - no response received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk “[R]andomised, double-blind, double-dummy, placebo- and ac-
tive-(infliximab) controlled . . .” “randomised by centre”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Assessors, physicians and patients were blinded to the treatment
group assignment for 1 year”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Patients who discontinued the study early were considered as
non-responders”, used LOCF
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Selective reporting (reporting bias) Low risk Almost full participation to 6 months in all study arms
Smolen 2008
Methods RCT of 24 weeks
Participants Outpatient clinic, Multicentre international
Inclusion criteria
Adult patients with moderate-severe active RA (Arnett -swollen joint count of ≥ 6 and
tender joint count of ≥ 8 or CRP over 10 mg/L or ESR of 28 mm/h or more) for
≥ 6 months duration with inadequate response to methotrexate. Must have received
methotrexate for≥ 12 weeks before the start of the study (stable dose of 10-25 mg/week
for ≥ 8 weeks). All other DMARDs were discontinued before the start of the study:
leflunomide for ≥ 12 weeks (or ≥ 4 weeks after 11 days of standard cholestyramine
washout), anakinra for≥ 1week, etanercept for≥ 2weeks, and infliximabor adalimumab
for ≥ 8 weeks. Oral glucocorticoids (≤ 10 mg/day prednisone or equivalent) and non-
steroidal anti-inflammatory drugs (NSAIDs) were permitted if doses were stable for 6
weeks or more before inclusion
Exclusions
Other autoimmune diseases or significant systemic involvement secondary to RA; func-
tional class IV RA; previous or current inflammatory joint disease other than rheumatoid
arthritis; active/previous recurrent bacterial, viral, fungal or other infections; clinically
significant abnormalities on chest radiograph, hepatitis B and C; or recurrent herpes
zoster. Active liver disease, previous unsuccessful treatment with an anti-TNF agent due
to lack of efficacy/significant safety issues
Group 1, 2 and 3
Gender (percentage female): 82%, 85% and 78% respectively
Age, mean (SD) years: 51.4 (12.8), 50.8 (11.8) and 50.6 (12.1) respectively
Interventions IV tocilizumab 4 weekly: 4mg/kg or 8mg/kg. All patients received drug in combination
with weekly administration of their stable dose of methotrexate.
If ACR 20 not achieved by week 16, patients in all arms given rescue therapy with
tocilizumab 8 mg/kg and, if necessary, intra-articular steroids or an increase in oral
corticosteroid
Group 1: Tocilizumab 4mg/kg IV + MTX
Group 2: Tocilizumab 8 mg/kg IV + MTX
Group 3: Placebo IV + MTX
Outcomes Primary outcome: ACR 20 at week 24 weeks
Secondary outcomes:
• ACR50 and ACR70 response at 24 weeks
• Change from baseline in DAS28 at 24 weeks
• Proportion of patients in DAS28 remission (DAS28 <2·6) at 24 weeks,
• EULAR response at 24 weeks
• Pain score (VAS 0-100mm)
• Patient’s global assessment of disease activity (VAS 0-100mm)
• Physician’s global assessment of disease activity (VAS 0-100mm)
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• HAQ-DI
• SF-36 at baseline and weeks 8, 16, and 24
• FACIT-F at baseline and every 4 weeks
Exclusions Other autoimmune diseases or significant systemic involvement secondary to RA; func-
tional class IV RA; previous or current inflammatory joint disease other than rheumatoid
arthritis; active/previous recurrent bacterial, viral, fungal or other infections; clinically
significant abnormalities on chest radiograph, hepatitis B and C; or recurrent herpes
zoster. Active liver disease, previous unsuccessful treatment with an anti-TNF agent due
to lack of efficacy/significant safety issues
Fatigue outcomes FACIT-F, 0-52, high = good
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was done centrally with an interactive voice re-
sponse system stratified by site with a randomization list pro-
vided by Roche”
Allocation concealment (selection bias) Low risk “Randomization was done centrally with an interactive voice re-
sponse system stratified by site with a randomization list pro-
vided by Roche”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Physician blinded to treatment, placebo-controlled interven-
tion, trained assessor with no access to data
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT done, LOCF for joints
Selective reporting (reporting bias) Low risk Fatigue was reported in the main study publication
Smolen 2009a
Methods RCT of 24 weeks
Participants Outpatient clinic, Multicentre international
Inclusion criteria
Aged > 18 years, diagnosis of RA (ACR) > 6 months’ duration but not longer than 15
years, active disease at screening and baseline. Patients had to have received prior MTX
for > 6months (stable dose > 10mg/week for > 2months before baseline). Supplementary
list of inclusion criteria available at: http://ard.bmj.com/content/vol68/issue6
Exclusions
Patients who received any biological agent for RA within 6 months before enrolment (3
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months for etanercept and anakinra), previous treatment with a biological agent resulting
in a severe hypersensitivity or anaphylactic reaction, or had not initially responded to
previous anti-TNF therapy. Oral corticosteroids (≤ 10 mg/day prednisone equivalent)
and non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors were per-
mitted provided that the doses were stable within 28 and 14 days of baseline, respectively,
and remained stable during the study. Patients with history of, or positive chest x-ray
findings for, tuberculosis, or a positive PPD skin test (defined as positive indurations per
local medical practice) were excluded.
Supplementary list of exclusion criteria available at: http://ard.bmj.com/content/vol68/
issue6
Group 1, 2 and 3
Gender (percentage female): 84.3%, 83.7%, and 78% respectively
Age, mean (SD) years: 51.5 (11.8), 52.2 (11.1), and 51.9 (11.8) respectively
Interventions Patients were randomised 2:2:1 to one of two regimens of subcutaneous liquid cer-
tolizumab pegol (400 mg at weeks 0, 2 and 4, followed by 200 or 400 mg every 2 weeks)
plus MTX for 24 weeks
Group 1: Placebo SC + MTX
Group 2: Certolizumab pegol 200 mg SC + MTX
Group 2: Certolizumab pegol 400 mg SC + MTX
Outcomes Primary outcome: ACR 20 response at 24 weeks
Secondary outcomes at 24 weeks:
• ACR 50 and 70
• Mean change from baseline in van der Heijde modified Total Sharp Scores
(mTSS)
• Disease activity using the DAS 28-joint assessment SF-36 PCS, MCS and PF
• Patient’s and physician’s global assessment of disease activity
• Patient’s assessment of arthritic pain
• Radiographic and safety assessments
Exclusions Patients who received any biological agent for RA within 6 months before enrolment (3
months for etanercept and anakinra), previous treatment with a biological agent resulting
in a severe hypersensitivity or anaphylactic reaction, or had not initially responded to
previous anti-TNF therapy. Oral corticosteroids (≤ 10 mg/day prednisone equivalent)
and non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors were per-
mitted provided that the doses were stable within 28 and 14 days of baseline, respectively,
and remained stable during the study. Patients with history of, or positive chest x-ray
findings for, tuberculosis, or a positive PPD skin test (defined as positive indurations per
local medical practice) were excluded.
Supplementary list of exclusion criteria available at: http://ard.bmj.com/content/vol68/
issue6
Fatigue outcomes SF-36 VT, range 0-100, high = good
Fatigue analogue scale, range 0-10, high = bad
Notes -
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were randomised 2:2:1
Allocation concealment (selection bias) Unclear risk Patients were randomised 2:2:1
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Nomention as to whether placebo looked identical; radiographs
were read centrally and blinded (for treatment, visit and patient
identification) and independently by 2 experienced readers but
not clear if nurses taking joint counts were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT
Selective reporting (reporting bias) Low risk Fatigue was reported in the main study publication
Smolen 2009b
Methods RCT of 24 weeks
Participants Outpatient clinic, Multicentre international
Inclusion criteria
Both a swollen joint count (66 joints) and tender joint count (68 joints) of > 8 at screening
and at baseline, a CRP level of > 1.0 mg/dL; receiving < 10 mg/day of prednisolone or
equivalent (if stable for at least 4 weeks prior to baseline) or NSAIDs (if stable for at least
2 weeks prior to baseline)
Exclusions
Inflammatory diseases other than rheumatoid arthritis; a serious adverse reaction to a
previous TNFα inhibitor (judged by the investigator); had ever received natalizumab or
rituximab; had received anakinra less than 4 weeks, or alefacept or efalizumab less than
3 months before the first dose of study drug; had ever received cytotoxic drugs; had a
history of latent or active granulomatous infection, except latent tuberculosis, that was
treated prophylactically in the past 3 years; had a BCG vaccination less than 12 months
before screening; had an opportunistic infection less than 6months before screening; had
a serious infection (judged by the investigator) less than 2 months before screening; had
a history of chronic infection, demyelinating disease, congestive heart failure, or severe,
progressive, uncontrolled renal, hepatic, haematological, gastric intestinal, endocrine,
pulmonary, cardiac, neurological, psychiatric, or cerebral disease; or had a transplanted
organ or a malignancy in the past 5 years
Group 1, 2 and 3
Gender (percentage female): 85%, 74%, and 80% respectively
Age, median (range) years: 54 (46-645), 55 (46-63), and 55 (47-61) respectively
Interventions Subcutaneous injections of 50 mg golimumab or 100 mg golimumab every 4 weeks.
Every patient received a 0.5 mL and a 1 mL injection every 4 weeks. Patients in the 50
mg group received golimumab in the 0.5 mL syringe and placebo in the 1 mL syringe,
whereas those in the 100 mg group received golimumab in the 1 mL syringe and placebo
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in the 0.5 mL syringe. Total = 4 doses. At week 16, patients in the 50 mg group who
had less than 20% improvement from baseline in both tender and swollen joint counts
entered a double-blinded rescue therapy phase to receive 100 mg golimumab. Patients
in the 100 mg group who met the criteria for rescue therapy continued to receive the
same dose. Change of treatment to rescue therapy was not possible at any other time
point
Group 1: Placebo SC
Group 2: Golimumab 50mg SC
Group 3: Golimumab 100mg SC
Outcomes Primary outcome: ACR 20 at week 14
Secondary outcome:
• ACR 20 at week 24
• ACR 50 and ACR 70 at weeks 14 and 24
• Numeric index of the ACR response at weeks 14 and 24
• DAS 28 at weeks 14 and 24
• HAQ-DI scores at weeks 14 and 24
• DAS 28 response according to EULAR (DAS 28 ≤ 5.1 and improvement from
base line > 0.6, or improvement from baseline > 1.2)
• DAS 28 remission (DAS 28 < 2.6).
• Serum samples taken at baseline and week 24 were assayed for the presence of
antibodies to golimumab
Exclusions Inflammatory diseases other than rheumatoid arthritis; a serious adverse reaction to a
previous TNFα inhibitor (judged by the investigator); had ever received natalizumab or
rituximab; had received anakinra less than 4 weeks, or alefacept or efalizumab less than
3 months before the first dose of study drug; had ever received cytotoxic drugs; had a
history of latent or active granulomatous infection, except latent tuberculosis, that was
treated prophylactically in the past 3 years; had a BCG vaccination less than 12 months
before screening; had an opportunistic infection less than 6months before screening; had
a serious infection (judged by the investigator) less than 2 months before screening; had
a history of chronic infection, demyelinating disease, congestive heart failure, or severe,
progressive, uncontrolled renal, hepatic, haematological, gastric intestinal, endocrine,
pulmonary, cardiac, neurological, psychiatric, or cerebral disease; or had a transplanted
organ or a malignancy in the past 5 years
Fatigue outcomes FACIT-F, 0-52, high = good
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomly assigned in a 1:1:1 ratio to receive sub-
cutaneous injections of placebo, 50 mg golimumab, or 100 mg
golimumab every 4weeks. Randomisationwas stratified by study
site and baseline methotrexate use.
Site personnel called a central telephone interactive voice re-
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sponse system (IVRS) to obtain randomisation information for
every patient
Allocation concealment (selection bias) Low risk Both patients and investigators were masked to treatment as-
signment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Including packaging and even when eligible for rescue package
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Patients with missing data were assumed to be non-responders
as were those who dropped out. ITT used. Doesn’t say how fa-
tigue scores were calculated where the data weremissing: LOCF?
Imputed?
Selective reporting (reporting bias) Low risk Fatigue was reported in the main study publication
Soubrier 2009
Methods RCT of 1 year
Participants Outpatient clinics, multicentre in France
Inclusion criteria
Maximum disease duration of 6 months
≥ 18 years of age
Active disease defined as a DAS 28 ESR (DAS 28) > 5.1
Screened for tuberculosis; patients who were at high risk for tuberculosis were allowed
to enrol in the study after chemoprophylaxis
Group 1, 2 3, and 4
Gender (percentage female): 83.8%, 84.3%, 84.9% and 78.6% respectively
Age, mean (SD) years: 48.6 (12.91), 48.2 (12.85), 50.9 (11.32) and 50.6 (11.58) re-
spectively
Exclusions
Previous treatment with MTX or biologics
Concomitant treatment with an experimental drug
Malignancy within the previous 10 years
Cytopaenia (haemoglobin < 9 g/dL in men, 8.5 g/dL in women, leucocytes < 3x109/L,
platelets < 150x109/L)
Serum aspartate aminotransferase/alanine aminotransferase level more than 1.5 times
the upper limit of normal
Creatinine clearance level < 50 mL/min
Concurrent pregnancy, inadequate contraception
Chronic infectious disease
Major episode of infection requiring hospitalisation or treatment with IV antibiotics
within 30 days or oral antibiotics within 14 days prior to screening
Heart disease, multiple sclerosis
Group 1 and Group 2:
Gender (percentage female): 81.25% and 78.79% respectively
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Age mean (SD) year: 49.3 (15.2) and 46.3 (16.3) respectively
Interventions Initial combination therapywithMTXandADA (Group 2): 0.3mg/kg/week,maximum
of 20 mg/week
Every 3 months decided whether or not to escalate based on DAS 28. If the patient did
not achieve a low disease activity (DAS 28 < 3.2), the treating physician immediately
adjusted therapy by proceeding to the next step in the allocated treatment group.
If the DAS 28 was < 3.2 at week 12, ADA was stopped. In the event of remission (DAS
28 < 2.6 for at least 6 months), MTX was tapered (2.5 mg/month) to a maintenance
dose of 7.5 mg/week. If disease activity flared after tapering of MTX, the initial dose
of MTX was reintroduced. In the event of relapse, patients restarted ADA 40 mg every
other week for 12 weeks. If the DAS 28 was > 3.2 after 12 weeks, ADA was stopped.
In the event of inefficacy (DAS 28 > 3.2 after 12 weeks of treatment), ADAwas increased
(40 mg/week) for 12 weeks. After 12 weeks of effective therapy, ADA was decreased
(40 mg every other week) for 12 weeks and stopped if successful. In the event of failure
on ADA 40 mg/week, etanercept (25 mg twice a week) was initiated for 12 weeks. If
effective, etanercept was stopped and started again for 12 weeks if relapse occurred. If
etanercept failed, LEF was initiated. If the treatment was unsuccessful after the initial
12 weeks, the same regimen was applied according to the protocol indicated above
Group 1: MTX
Group 2: MTX + ADA
Outcomes Primary outcome: proportion of patients in low disease activity at week 12 for whom
anti-TNF was not introduced or reintroduced at 1 year
Secondary outcomes:
• 1-year area under the curve (AUC) of DAS 28
• EULAR responders
• ACR responders (20, 50 and 70)
• Time to obtain low disease activity
• Number of visits at which the patients had low disease activity
• Number of anti-TNF doses over the 1-year period
• HAQ
• SF-36
• Swollen joints (0-28), tender joints (0-28)
• EMS
• VAS score for pain, general well-being
• VAS physician overall assessment
• ESR (mm per first hour)
• CRP (mg/L)
• Radiographs of hands and feet
Exclusions Previous treatment with MTX or biologics
Concomitant treatment with an experimental drug
Malignancy within the previous 10 years
Cytopaenia (haemoglobin < 9 g/dL in men, 8.5 g/dL in women, leucocytes < 3x109/L,
platelets < 150x109/L)
Serum aspartate aminotransferase/alanine aminotransferase level more than 1.5 times
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the upper limit of normal
Creatinine clearance level < 50 mL/min
Concurrent pregnancy, inadequate contraception
Chronic infectious disease
Major episode of infection requiring hospitalisation or treatment with IV antibiotics
within 30 days or oral antibiotics within 14 days prior to screening
Heart disease, multiple sclerosis
Fatigue outcomes VAS (visual analog scale), range 0-100, high = bad
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients randomised
Allocation concealment (selection bias) Unclear risk Patients randomised
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not possible, complex escalation regime dependent on
response
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients enrolled in the study were included in ITT analyses
of efficacy and safety. The LOCF approach was used to handle
missing data
Selective reporting (reporting bias) High risk This main paper does not give details of all outcomes, but does
summarise (e.g. had to get full fatigue data from authors)
Strand 2009
Methods RCT of 1 year
Participants Outpatient clinic, Multicentre international
Inclusion criteria
≥ 18 years of age, diagnosis of RA as defined by the ACR 1987 criteria, active disease
was defined as > 9 tender and 9 swollen joints at screening and at baseline, with either an
ESR > 30 mm/h or a CRP of > 15 mg/L. Patients were required to have received MTX
for > 6 months, with a stable dosage of > 10 mg/week for > 2 months prior to baseline
Exclusions
Diagnoses of any other inflammatory arthritis or a secondary non-inflammatory arthritis
that could have interfered with our evaluation of the effects of certolizumab pegol on
RA. Patients with a history of tuberculosis or a chest radiograph showing active or latent
tuberculosis. Patients with positive PPD skin test were excluded unless the PPDpositivity
was associated with previous vaccination with BCG. Patients who, in the investigator’s
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opinion, were at a high risk of infection.
History of malignancy, demyelinating disease, blood dyscrasias, or severe, progressive,
uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, car-
diac, neurologic or cerebral disease.
Patients who had received any biologic therapy within 6 months (or had received etan-
ercept or anakinra within 3 months) of baseline, or any previous biologic therapy that
resulted in a severe hypersensitivity or anaphylactic reaction were excluded, as were pa-
tients who had previously failed to respond to treatment with an anti-TNF agent
Group 1, 2 and 3
Gender (percentage female): 83.9%, 82.4% and 83.6% respectively
Age, mean (SD) years: 52.2 (11.2), 51.4 (11.6) and 52.4 (11.7) respectively
Interventions All patients received stable doses of methotrexate
Subcutaneous injections of certolizumab over 52 weeks
Loading doses of 400 mg at 0, 2 and 4 then 200 mg or 400 mg every other week. Total
27 injections
Group 1: Placebo + MTX
Group 2: Certolizumab 200mg + MTX
Group 3: Certolizumab 400mg + MTX
Outcomes From Keystone 2008:
Primary Outcomes:
• ACR 20 at week 24
• X-rays: mean change in modified total Sharp score at week 52
Secondary Outcomes
• HAQ
• patient’s global assessment of disease
• physician global assessment of disease
• pain
• DAS 28
• inflammatory indices
• vital signs
• bloods
• urine
• BP.
• fatigue NRS
• SF-36 domains
Exclusions Diagnoses of any other inflammatory arthritis or a secondary non-inflammatory arthritis
that could have interfered with our evaluation of the effects of certolizumab pegol on
RA. Patients with a history of tuberculosis or a chest radiograph showing active or latent
tuberculosis. Patients with positive PPD skin test were excluded unless the PPDpositivity
was associated with previous vaccination with BCG. Patients who, in the investigator’s
opinion, were at a high risk of infection.
History of malignancy, demyelinating disease, blood dyscrasias, or severe, progressive,
uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, car-
diac, neurologic or cerebral disease.
Patients who had received any biologic therapy within 6 months (or had received etan-
ercept or anakinra within 3 months) of baseline, or any previous biologic therapy that
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resulted in a severe hypersensitivity or anaphylactic reaction were excluded, as were pa-
tients who had previously failed to respond to treatment with an anti-TNF agent
Fatigue outcomes SF-36 VT, range 0-100, high = good
Fatigue numerical rating scale, range 0-10, high = bad
Notes Patients who failed to achieve a response the ACR 20 at weeks 12 and 14 were designated
treatment failures andwere withdrawn from the study at week 16. Patients who withdrew
at week 16 or who successfully completed the trial were offered enrolment in an open-
label extension study of certolizumab pegol 400mg every 2weeks. Patients whowithdrew
early for reasons other than withdrawal of consent underwent mandatory radiographic
assessment at the time of withdrawal and at week 52
Mean change/SDS not reported for NRS
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “[R]andomized 2:2:1” but no details
Allocation concealment (selection bias) Unclear risk “[R]andomized 2:2:1” but no details
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT
Selective reporting (reporting bias) High risk Post hoc analysis from another trial
Strand 2012a
Methods RCT of 24 weeks
Participants Outpatient clinic, Multicentre international
Inclusion criteria
≥ 18 years of age, moderate to severe active RA, failure to respond or intolerance to
one or more TNF antagonists within the past year, active RA for 6 months or more,
swollen joint count of ≥ 6, tender joint count of ≥ 8, CRP greater than 1.0 mg/dL or
ESR greater than 28 mm/h. Patients had to be treated with MTX for 12 weeks or more
before baseline
(stable dose > 8 weeks)
Exclusions
Treatment with cell depleting agents
Uncontrolled medical conditions
Other inflammatory diseases
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Functional class IV RA
History ofmalignancies or recurrent infections, primary or secondary immunodeficiency
Haemoglobin less than 8.5 g/dL, leucopaenia, neutropaenia, thrombocytopaenia
Abnormal liver function, triglycerides greater than 10 mmol/L,
Active tuberculosis, hepatitis B, or hepatitis C.
Group 1, 2 and 3
Gender (percentage female): 79%, 81%, and 84% respectively
Age, mean (SD) years: 53.4 (13.3), 50.9 (12.5), and 53.9 (12.7) respectively
Interventions 4 mg/kg tocilizumab IV once every 4 weeks
Stable doses (10-25 mg) of weekly MTX for 24 weeks
or
8 mg/kg tocilizumab IV once every 4 weeks
Stable doses (10-25 mg) of weekly MTX for 24 weeks.
Group 1: Placebo + MTX
Group 2: Tocilizumab 4mg/kg + MTX
Group 2: Tocilizumab 8mg/kg + MTX
Outcomes Primary outcome: ACR 20 response at week 24
Secondary outcomes:
• Pain and PtGA, evaluated using VAS
• HAQ
• SF-36 version 2, SF-6D scores for health utilities
Exclusions Treatment with cell depleting agents
Uncontrolled medical conditions
Other inflammatory diseases
Functional class IV RA
History ofmalignancies or recurrent infections, primary or secondary immunodeficiency
Haemoglobin less than 8.5 g/dL, leucopaenia, neutropaenia, thrombocytopaenia
Abnormal liver function, triglycerides greater than 10 mmol/L,
Active tuberculosis, hepatitis B, or hepatitis C.
Fatigue outcomes SF-36 VT, 0-100, high = good
FACIT-F, range: 0-52, high = good
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “[R]andomised, double-blind” but no details
Allocation concealment (selection bias) Unclear risk “[R]andomised, double-blind” but no details
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Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Joint counts? Analysis?
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT
Selective reporting (reporting bias) High risk Post hoc analysis from another trial
Strand 2012b
Methods RCT of 2 years
Participants Outpatient clinic, multicentre international
Inclusion criteria
MTX-naive patients ≥ 18 years of age with
active RA (≥ 8 swollen joints, ≥ 10 tender joints, and an erythrocyte sedimentation
rate ≥ 28 mm/h or CRP concentration ≥ 1.5 mg/dL, in addition to rheumatoid factor
positivity or ≥ 1 joint erosion) and disease duration < 3 years
Exclusions
not stated
Group 1, 2 and 3
Gender (percentage female): 72%, 73.9% and 77.4% respectively
Age, mean (SD) years: 51.9 (14), 52.0 (13.1) and 52.1 (13.5)
Interventions Adalimumab (ADA) 40 mg subcutaneously every other week plus weekly oral MTX,
104 weeks
Group 1: ADA + MTX
Group 2: Placebo + MTX
Group 3: ADA + placebo
[only extract adalimumab plus methotrexate (group 1) vs methrotrexate (group 2) for
review]
Outcomes Primary outcomes (at 52 weeks):
• ACR 50 response
• Radiographic data by modified total Sharp score
Secondary outcomes:
• ACR 20/50/70/90 responses
• Radiographic data by modified total Sharp score at week 104
• Physical function
• HRQoL data at week 104
Exclusions -
Fatigue outcomes FACIT-F, 0-52, High good
Notes -
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Strand 2012b (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “[R]andomised, double-blind” but no details
Allocation concealment (selection bias) Unclear risk “[R]andomised, double-blind” but no details
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Patients were randomized to 1 of 3 treatment groups: adali-
mumab 40mg subcutaneously every other week plus weekly oral
MTX (20 mg/week); adalimumab 40 mg subcutaneously every
other week (adalimumab plus placebo); or weekly oral MTX
(MTX plus placebo). Hence, all patients received an
injection (adalimumab or placebo) and an oral medication
(MTX or placebo)
Incomplete outcome data (attrition bias)
All outcomes
Low risk ACR responses were calculated using an ITT analysis, for which
patients who discontinued the study
prior to reaching the end point were considered to be non-
responders
Selective reporting (reporting bias) High risk Post hoc analysis from another trial
Weinblatt 2003
Methods RCT of 24 weeks
Participants Outpatient clinic, Multicentre international
Inclusion criteria
≥ 18 years, RA (1987 revised criteria of ACR); active disease (at least 9/68 tender joints
and 6/66 swollen joints). Must have been treated with MTX for ≥ 6 months and taking
a stable weekly dose (12.5-25 mg, or 10 mg if intolerant to higher doses) for ≥ 4 weeks
before entering the study. All participants must have failed treatment with at least 1
DMARD besides MTX, but no more than 4 DMARDs
Exclusions
For all patients: all DMARDs, except MTX, were discontinued 4 weeks before the study.
In addition to MTX, concomitant RA therapies permitted during the study included
salicylates, NSAIDs and corticosteroids (maximum daily dose of 10 mg of oral pred-
nisone or equivalent). Dosage tapering or changes in the route of administration of the
concomitant medications were not permitted during the study. Folic acid or leucovorin
was permitted. High potency opioid analgesics (e.g., methadone, hydromorphone or
morphine) were prohibited; other analgesics were allowed, although not within 12 h of
study visits
Group 1, 2 3, and 4
Gender (percentage female): 82.3%, 75.4%, 74.6% and 75.3% respectively
Age, mean (SD) years: 56.0 (10.8), 53.5 (12.4), 57.2 (11.4) and 55.5 (11.7) respectively
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Weinblatt 2003 (Continued)
Interventions Patients were randomised to receive adalimumab at a dosage of 20 mg, 40 mg, or 80 mg
subcutaneously every other week as 2 injections of 1.6 mL per injection. Patients were
instructed in self injection techniques
Group 1: Placebo SC every other week + MTX
Group 2: Adalimumab 20mg SC every other week + MTX
Group 3: Adalimumab 40mg SC every other week + MTX
Group 4: Adalimumab 80mg SC every other week + MTX
Outcomes Primary outcome: percentage of patients achieving ACR 20 response at week 24
Secondary outcomes:
• ACR 50 and the ACR 70 response rates
• Tender joint count
• Swollen joint count
• Patient’s assessment of pain
• Patient’s global assessment of disease activity
• Physician’s global assessment of disease activity
• HAQ DI
• Serum levels of CRP.
• Short Form 36 (SF-36)
• Fatigue scale of the FACIT.
• Serum concentrations of the cartilage destruction markers pro-matrix
metalloproteinase 1 (proMMP-1) and proMMP-3
Exclusions Standard exclusion criteria used in trials of other biologics in patients with RA, also
patients who had received anti-CD4 therapy or TNF antagonists, had a history of active
listeriosis or mycobacterial infection, and had a major episode of infection requiring
hospitalisation or treatment with IV antibiotics within 30 days or oral antibiotics within
14 days prior to screening
Fatigue outcomes SF-36 VT, 0-100, high = good
FACIT-F, range: 0-52, high = good
Notes For all patients: all DMARDs, except MTX, were discontinued 4 weeks before the study.
In addition to MTX, concomitant RA therapies permitted during the study included
salicylates, NSAIDs and corticosteroids (maximum daily dose of 10 mg of oral pred-
nisone or equivalent). Dosage tapering or changes in the route of administration of the
concomitant medications were not permitted during the study. Folic acid or leucovorin
was permitted. High potency opioid analgesics (e.g., methadone, hydromorphone or
morphine) were prohibited; other analgesics were allowed, although not within 12 h of
study visits
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “[R]andomized” but no details
73Biologic interventions for fatigue in rheumatoid arthritis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Allocation concealment (selection bias) Unclear risk “[R]andomized” but no details
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk LOCF
Selective reporting (reporting bias) Low risk Fatigue was reported in the main study publication
Weinblatt 2013
Methods RCT of 100 weeks
Participants Outpatient clinic, Multicentre international
Inclusion criteria
Adults with active RA despite MTX (stable regimen of 15-25 mg/week for ≥ 4 weeks)
for ≥ 3 months
Active RA was defined by ≥ 6/66 swollen joints and ≥ 6/68 tender joints
RF positive or anti-CCP positive at screening, CRP ≥ 1.0 mg/dL
Naive to anti-TNF treatment
Stable (≥ 2 weeks) approved regimens of NSAIDs, oral corticosteroids (≤10 mg/day)
or both were allowed
Eligible patients met all relevant TB and clinical laboratory screening criteria. With
regard to TB, patients with no history of latent or active TB prior to screening, no signs
or symptoms suggestive of active TB upon medical history or physical examination, no
recent close contact with a person with active TB, a negative QuantiFERON-TBÒGold
In-Tube 2 test result within 6 weeks of study agent start, and a chest radiograph within 3
months prior to the first administration of study agent and read by a qualified radiologist.
Patients with evidence of close contact to active TB or latent TB could enroll in the
study if treated for latent TB prior to or simultaneously with the first administration of
study agent
Exclusions
DMARDs other than MTX or non-oral corticosteroids within the prior 4 weeks were
excluded
Prior receipt of: any commercial/investigational TNF-inhibitor; natalizumab or other
alpha-4-integrin blockers; or rituximab, abatacept or efalizumab
Patients with other inflammatory diseases, a known hypersensitivity to human im-
munoglobulin proteins or other components of golimumab
Prior receipt of any commercial or investigational anti-TNF therapy
History of latent or active granulomatous infection, including histoplasmosis, or coc-
cidioidomycosis prior to screening; had a bacille Calmette-Guérin vaccination within
12 months of screening; had a chest radiograph within 3 months prior to the first ad-
ministration of study agent that showed an abnormality suggestive of a malignancy or
current active infection, including TB; had a nontuberculous mycobacterial infection
or opportunistic infection (e.g. cytomegalovirus, pneumocystosis, aspergillosis) within
6 months prior to screening; or had received, or was expected to receive, any live virus
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or bacterial vaccination within 3 months prior to the first administration of study agent,
during the study, or within 6 months after the last
administration of study agent.
History of an infected joint prosthesis, receipt of antibiotics for a suspected infection
of a joint prosthesis, if that prosthesis has not been removed or replaced; a serious
infection (e.g., hepatitis, pneumonia, or pyelonephritis), hospitalisation for an infection,
or treatment of an infection with intravenous antibiotics within 2 months prior to the
first administration of study agent; a history of, or ongoing, chronic or recurrent (> 3
identical infections/12 months) infectious disease; an open, draining, or infected skin
wound; or an ulcer.
Patients with a history of known demyelinating diseases such as multiple sclerosis or
optic neuritis were excluded, as were patients with a history of, or concurrent, congestive
heart failure.
Patients with a history of lymphoproliferative disease, including lymphoma, or signs
suggestive of possible lymphoproliferative disease such as lymphadenopathy of unusual
size or location, or clinically significant splenomegaly were ineligible, as were patients
with any known malignancy or a history of malignancy within the previous 5 years (with
the exception of a treated nonmelanoma skin cancer with no evidence of recurrence)
Group 1 and 2
Gender (percentage female): 79.7% and 82.5% respectively
Age, mean (SD) years: 51.4 (11.26) and 51.9 (12.55) respectively
Interventions Intravenous golimumab 2mg/kg at weeks 0 and 4, and then every 8 weeks through week
100
Group 1: Placebo + MTX
Group 2: Glimumab 2mg/kg + MTX
Outcomes Primary outcome: ACR 20 at week 14
Secondary outcomes:
• EULAR good or moderate response
• Clinical remission (DAS 28 < 2.6)
• Simplified Disease Activity Index (SDAI)
• Clinical Disease Activity Index (CDAI)
Exclusions DMARDs other than MTX or non-oral corticosteroids within the prior 4 weeks were
excluded
Prior receipt of: any commercial/investigational TNF-inhibitor; natalizumab or other
alpha-4-integrin blockers; or rituximab, abatacept or efalizumab
Patients with other inflammatory diseases, a known hypersensitivity to human im-
munoglobulin proteins or other components of golimumab
Prior receipt of any commercial or investigational anti-TNF therapy
History of latent or active granulomatous infection, including histoplasmosis, or coc-
cidioidomycosis prior to screening; had a bacille Calmette-Guérin vaccination within
12 months of screening; had a chest radiograph within 3 months prior to the first ad-
ministration of study agent that showed an abnormality suggestive of a malignancy or
current active infection, including TB; had a nontuberculous mycobacterial infection
or opportunistic infection (e.g. cytomegalovirus, pneumocystosis, aspergillosis) within
6 months prior to screening; or had received, or was expected to receive, any live virus
or bacterial vaccination within 3 months prior to the first administration of study agent,
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Weinblatt 2013 (Continued)
during the study, or within 6 months after the last
administration of study agent.
History of an infected joint prosthesis, receipt of antibiotics for a suspected infection
of a joint prosthesis, if that prosthesis has not been removed or replaced; a serious
infection (e.g., hepatitis, pneumonia, or pyelonephritis), hospitalisation for an infection,
or treatment of an infection with intravenous antibiotics within 2 months prior to the
first administration of study agent; a history of, or ongoing, chronic or recurrent (> 3
identical infections/12 months) infectious disease; an open, draining, or infected skin
wound; or an ulcer.
Patients with a history of known demyelinating diseases such as multiple sclerosis or
optic neuritis were excluded, as were patients with a history of, or concurrent, congestive
heart failure.
Patients with a history of lymphoproliferative disease, including lymphoma, or signs
suggestive of possible lymphoproliferative disease such as lymphadenopathy of unusual
size or location, or clinically significant splenomegaly were ineligible, as were patients
with any known malignancy or a history of malignancy within the previous 5 years (with
the exception of a treated nonmelanoma skin cancer with no evidence of recurrence)
Fatigue outcomes FACIT-F, range: 0-52, high = good
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomly (2:1) assigned, via IVRS
Allocation concealment (selection bias) Low risk Patients were randomly (2:1) assigned, via IVRS
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind with placebo infusion. Joint evaluations were per-
formed by an independent blinded assessor assigned to each
study centre
Incomplete outcome data (attrition bias)
All outcomes
Low risk Patients with prohibited medication usage, who discontinued
because of lack of efficacy before week 14 and who lacked all
week 14 ACR 20 component data for any reason were consid-
ered ACR 20 non-responders at week 14 through week 24. In
these ITT analyses, patients randomised to placebo who early
escaped (EE) (n=68/197), and who received golimumab 2 mg/
kg infusions at weeks 16 and 20, had week 16 data carried for-
ward for response calculations at weeks 20 and 24. A LOCF
procedure was employed to impute missing ACR component
data (e.g. swollen or tender joint count, or global assessments of
disease) at week 14 if the patient had data for at least one other
ACR component at week 14
76Biologic interventions for fatigue in rheumatoid arthritis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Weinblatt 2013 (Continued)
Selective reporting (reporting bias) Unclear risk Didn’t mention fatigue data collected, presented as an abstract.
What else is missing?
ACR: American College of Rheumatology; ADA: adalimumab; BCG: bacille Calmette-Guerin; CCP: anti-cyclic citrullinated peptide
antibody; CDAI: Clinical Disease Activity Index; CORE: computerised randomisation and enrolment; CRP: C-reactive protein;
CS: corticosteroid; CTLA4Ig: cytotoxic T-lymphocyte-associated protein 4-immunoglobulin superfamily; CZP: certolizumab;
DAS: Disease Activity Score 28; DMARD: disease-modifying anti-rheumatic drugs; ETN: etanercept; EE: early escaped; EMS:
electronicmuscle therapy;EQ-5D: EuroQol five dimensions questionnaire;ESR: erythrocyte sedimentation rate;EULAR: European
League Against Rheumatism; FACIT-F: Functional Assessment of Chronic Illness Therapy-Fatigue; FAS: Fatigue Assessment Scale;
HADS: Hospital Anxiety and Depression Scale;HAQ (DI): Health Assessment Questionnaire (disability index); IA: intra-articular;
IM: intramuscular; INF: Infliximab; ITT: intention-to-treat; IUD: intrauterine device; IV: intravenous; IVRS: interactive voice
response system; LEF: leflumonide; LOCF: last observation carried forward;MTX: methotrexate;NRI: non-responder imputation;
NRS: numeric rating scale; NSAID: non-steroidal anti-inflammatory drug; PCS: physical component score; PPD: purified protein
derivative; PRO: patient-reported outcomes; RA: rheumatoid arthritis; RCT: randomised controlled trial;RF: rheumatoid factor;
RTX: Rituximab; SC: subcutaneous; SD: standard deviation; SDAI: Simplified Disease Activity Index; SF-6D: Short Form Six
Dimension questionnaire; SF-12v2: Short Form 12-item version 2 questionnaire; SF-36 (VT): Short Form 36-item questionnaire
(vitality); TCZ: Tocilizumab; TB: tuberculosis; TNF: tumour necrosis factor; VAS: visual analogue scale;WPAI: work productivity
and activity impairment.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Breedveld 2005 No fatigue outcome measure
Cella 2005 Not an RCT
Dougados 2007 CRA conference abstract. Full text of trial was published as Genovese 2005
Duggan 2009 Not an RCT
Elliott 1994 No fatigue outcome measure
Frampton 2007 Not an RCT
Furst 2003 No fatigue outcome measure
Genovese 2010 No fatigue outcome measure
Gnanasakthy 2013 Abstract only, same as published in Strand 2014
Grigor 2004 No fatigue outcome measure
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Haugeberg 2009 No fatigue outcome measure
Kavanaugh 2003 No fatigue outcome measure
Kavanaugh 2012 Not an RCT
Kim 2007 No fatigue outcome measure
Kosinski 2000 No fatigue outcome available
Kremer 2008 No fatigue outcome measure
Moreland 2000 No fatigue outcome measure
Moreland 2002 No fatigue outcome measure
Sansonno 2003 Not an RCT
Song 2007 No fatigue outcome measure
Strand 2012 Reported fatigue was a factor that influenced work productivity but not the result of RCT
Strand 2014 Report the effect of different doses of seculimumab on fatigue before and after treatment but not between active
and placebo nor usual care
Tak 2008 No fatigue outcome measure
Yount 2007 Not an RCT
Characteristics of ongoing studies [ordered by study ID]
St Clair 2004
Trial name or title Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled
trial
Methods -
Participants -
Interventions -
Outcomes -
Starting date
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St Clair 2004 (Continued)
Contact information
Notes -
Van der Kooij 2009
Trial name or title Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset
rheumatoid arthritis
Methods -
Participants -
Interventions -
Outcomes -
Starting date
Contact information
Notes -
Westhovens 2006
Trial name or title Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have
inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized
clinical trial
Methods -
Participants -
Interventions -
Outcomes -
Starting date
Contact information
Notes -
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D A T A A N D A N A L Y S E S
Comparison 1. All biologics
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All studies - fatigue continuous
measures
30 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 All biologics 30 14628 Std. Mean Difference (IV, Random, 95% CI) -0.43 [-0.49, -0.38]
Comparison 2. Subgroup comparison: anti-TNF vs non-anti-TNF
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Anti-TNF and non anti-TNF -
fatigue continuous measures
30 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Anti-TNF 19 8946 Std. Mean Difference (IV, Random, 95% CI) -0.42 [-0.49, -0.35]
1.2 Non-anti-TNF 11 5682 Std. Mean Difference (IV, Random, 95% CI) -0.46 [-0.53, -0.39]
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Analysis 1.1. Comparison 1 All biologics, Outcome 1 All studies - fatigue continuous measures.
Review: Biologic interventions for fatigue in rheumatoid arthritis
Comparison: 1 All biologics
Outcome: 1 All studies - fatigue continuous measures
Study or subgroup Biologics Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 All biologics
Alten 2011 64 -2.5 (9.2) 23 0 (9.4) 1.0 % -0.27 [ -0.75, 0.21 ]
Alten 2011 69 -4.4 (9.3) 23 0 (9.4) 1.0 % -0.47 [ -0.94, 0.01 ]
Alten 2011 71 -3.5 (9.4) 23 0 (9.4) 1.0 % -0.37 [ -0.84, 0.10 ]
Bae 2013 193 -8.1 (10.42) 88 -3.1 (10.42) 2.2 % -0.48 [ -0.73, -0.22 ]
Choy 2012 119 -14.72 (19.165) 102 -3.74 (17.833) 2.1 % -0.59 [ -0.86, -0.32 ]
Cohen 2006 298 -13.97 (22.34) 201 -3.32 (21.09) 2.9 % -0.49 [ -0.67, -0.31 ]
Emery 2006 122 -6.02 (10.82) 61 -2.69 (7.42) 1.8 % -0.34 [ -0.65, -0.03 ]
Emery 2006 (1) 123 -6.71 (10.65) 61 -2.69 (7.42) 1.8 % -0.41 [ -0.72, -0.10 ]
Emery 2008 265 -21.4 (22.9) 263 -16.7 (21.9) 3.1 % -0.21 [ -0.38, -0.04 ]
Emery 2009 302 -7.21 (9.666) 151 -6.2 (10.896) 2.8 % -0.10 [ -0.30, 0.10 ]
Fleischmann 2009 (2) 111 -10.73 (24.327) 109 -1.88 (17.649) 2.1 % -0.41 [ -0.68, -0.15 ]
Genovese 2005 258 -5.6 (10.96) 133 0 (10.96) 2.6 % -0.51 [ -0.72, -0.30 ]
Genovese 2008 724 -8.1 (10.53) 321 -3.3 (9.56) 3.5 % -0.47 [ -0.60, -0.34 ]
H rslev-Petersen 2014 89 -33.1 (32.9) 91 -23.3 (31.3) 1.9 % -0.30 [ -0.60, -0.01 ]
Keystone 2004 200 -16.55 (21.95) 96 -7.87 (21.3) 2.3 % -0.40 [ -0.64, -0.15 ]
Keystone 2004 (3) 206 -15.1 (21.94) 96 -7.87 (21.3) 2.3 % -0.33 [ -0.58, -0.09 ]
Keystone 2009 89 -7.16 (8.58) 67 -2.16 (9.53) 1.7 % -0.55 [ -0.88, -0.23 ]
Keystone 2009 89 -7.3 (8.65) 66 -2.16 (9.53) 1.7 % -0.57 [ -0.89, -0.24 ]
Kremer 2003 115 -7.9 (8.579) 60 -2.1 (8.727) 1.7 % -0.67 [ -0.99, -0.35 ]
Kremer 2003 (4) 105 -3.5 (8.198) 59 -2.1 (8.727) 1.7 % -0.17 [ -0.49, 0.15 ]
Kremer 2006 (5) 433 -7.3 (9.669) 219 -4.8 (9.875) 3.2 % -0.26 [ -0.42, -0.09 ]
Li 2013 132 -3.4 (9.4) 132 2.2 (11.2) 2.3 % -0.54 [ -0.79, -0.29 ]
Mittendorf 2007 (6) 99 -8.65 (10.19) 93 -3.33 (7.67) 1.9 % -0.59 [ -0.87, -0.30 ]
Moreland 1999 76 -22 (63.2) 40 -2 (63.2) 1.3 % -0.31 [ -0.70, 0.07 ]
-2 -1 0 1 2
Favours biologics Favours control
(Continued . . . )
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Study or subgroup Biologics Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Moreland 1999 (7) 78 -25 (73.17) 40 -2 (63.2) 1.3 % -0.33 [ -0.71, 0.06 ]
Pope 2012 851 -1.3 (3.16) 212 -0.5 (3.16) 3.3 % -0.25 [ -0.40, -0.10 ]
Rigby 2011 250 -10.282 (27.15) 125 6.83 (11.27) 2.5 % -0.74 [ -0.96, -0.52 ]
Rigby 2011 249 -9.362 (27.25) 124 6.83 (11.27) 2.5 % -0.70 [ -0.92, -0.48 ]
Schiff 2008 (8) 165 -7 (10.5) 55 -3.5 (10) 1.8 % -0.34 [ -0.64, -0.03 ]
Schiff 2008 156 -8 (10) 55 -3.5 (10) 1.8 % -0.45 [ -0.76, -0.14 ]
Smolen 2008 (9) 172 -9.2 (10.8) 61 -4.4 (8.7) 1.9 % -0.46 [ -0.76, -0.17 ]
Smolen 2008 154 -8.4 (10.1) 61 -4.4 (8.7) 1.8 % -0.41 [ -0.71, -0.11 ]
Smolen 2009a 246 -13.45 (19.52) 63 -2.76 (17.8) 2.0 % -0.56 [ -0.84, -0.28 ]
Smolen 2009a (10) 246 -2.1 (2.3) 63 -0.5 (2) 2.0 % -0.71 [ -0.99, -0.43 ]
Smolen 2009a 246 -12.64 (16.53) 64 -2.76 (17.8) 2.0 % -0.59 [ -0.87, -0.31 ]
Smolen 2009a 246 -2.1 (2.1) 64 -0.5 (2) 2.0 % -0.77 [ -1.05, -0.49 ]
Smolen 2009b 153 -5 (10.37) 77 -1 (8.89) 2.0 % -0.40 [ -0.68, -0.13 ]
Smolen 2009b 153 -6 (10.37) 76 -1 (8.89) 2.0 % -0.50 [ -0.78, -0.22 ]
Soubrier 2009 33 -33.5 (26.6) 32 -41.5 (29) 0.9 % 0.28 [ -0.20, 0.77 ]
Strand 2009 393 -12.9 (25.77) 100 -2.8 (16) 2.5 % -0.42 [ -0.64, -0.20 ]
Strand 2009 (11) 390 -14.4 (27.65) 99 -2.8 (15.92) 2.5 % -0.45 [ -0.67, -0.23 ]
Strand 2012a 161 -6.66 (9.77) 79 -3.03 (8.42) 2.1 % -0.39 [ -0.66, -0.12 ]
Strand 2012a 170 -9.07 (10.4) 79 -3.03 (8.42) 2.0 % -0.61 [ -0.89, -0.34 ]
Strand 2012b 265 -14.6 (17.82) 254 -13.5 (17.82) 3.1 % -0.06 [ -0.23, 0.11 ]
Weinblatt 2003 69 -5.8 (9.9) 21 -2.6 (10.1) 0.9 % -0.32 [ -0.81, 0.17 ]
Weinblatt 2003 67 -8.1 (11.2) 21 -2.6 (10.1) 0.9 % -0.50 [ -0.99, 0.00 ]
Weinblatt 2003 69 -15.2 (20.5) 21 -5.4 (23.8) 0.9 % -0.46 [ -0.95, 0.04 ]
Weinblatt 2003 (12) 75 -10 (10.8) 20 -2.6 (10.1) 0.9 % -0.69 [ -1.19, -0.19 ]
Weinblatt 2003 67 -18.3 (26.8) 21 -5.4 (23.8) 0.9 % -0.49 [ -0.99, 0.01 ]
Weinblatt 2003 75 -20.9 (20.9) 20 -5.4 (23.8) 0.9 % -0.71 [ -1.22, -0.21 ]
Weinblatt 2013 395 -8 (10.8) 197 -2.5 (10.2) 3.0 % -0.52 [ -0.69, -0.34 ]
Subtotal (95% CI) 9946 4682 100.0 % -0.43 [ -0.49, -0.38 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 96.50, df = 50 (P = 0.00009); I2 =48%
Test for overall effect: Z = 16.14 (P < 0.00001)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours biologics Favours control
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(1) SF36-V; R500 v Ctrl. Half n entered for ctrl. Reversed score so High=bad; From Table 2 in Mease 2008
(2) SF36-V; Reversed score so High=bad; Unpublished data provided by author
(3) SF36-V: Ad40 v ctrl; Half n entered for ctrl. Reversed score so High=bad
(4) SF36-V: Ab 10mg v ctrl; Half n entered for ctrl. Reversed score so High=bad. Change sds calculated by review statistician
(5) SF36-V 12mths. Reversed score so High=bad. Change sds calculated by review statistician.
(6) FACIT-F; reversed score so High=bad; Unpublished data provided by author
(7) SF36-V: Etan 10mg v ctrl; Half n entered for ctrl. Reversed score so High=bad. Change sds calculated by review statistician.
(8) SF-36V change scores at 6mths: Abat v ctrl; Half n entered for ctrl. Reversed score so High=bad Unpublished baseline data provided by author. Placebo arm stopped
at 6 months.
(9) FACIT-F; Toc 4mg v ctrl; Half n entered for ctrl. Reversed score so High=bad: CHECK N to be shown: Unpublished data provided by author
(10) SF36-V; CZP 200mg Half n entered for ctrl. Reversed score so High=bad; Unpublished data provided by author
(11) Week 12 SF36-V; CZP 200mg v ctrl. Half n entered for ctrl. Reversed score so High=bad
(12) SF36-V; Ad 20mg Third of n entered for ctrl. Reversed score so High=bad; Unpublished data provided by author
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Analysis 2.1. Comparison 2 Subgroup comparison: anti-TNF vs non-anti-TNF, Outcome 1 Anti-TNF and
non anti-TNF - fatigue continuous measures.
Review: Biologic interventions for fatigue in rheumatoid arthritis
Comparison: 2 Subgroup comparison: anti-TNF vs non-anti-TNF
Outcome: 1 Anti-TNF and non anti-TNF - fatigue continuous measures
Study or subgroup Biologics Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Anti-TNF
Bae 2013 193 -8.1 (10.42) 88 -3.1 (10.42) 3.6 % -0.48 [ -0.73, -0.22 ]
Choy 2012 119 -14.72 (19.165) 102 -3.74 (17.833) 3.4 % -0.59 [ -0.86, -0.32 ]
Emery 2008 (1) 265 -21.4 (22.9) 263 -16.7 (21.9) 4.7 % -0.21 [ -0.38, -0.04 ]
Emery 2009 302 -7.21 (9.666) 151 -6.2 (10.896) 4.4 % -0.10 [ -0.30, 0.10 ]
Fleischmann 2009 (2) 111 -10.73 (24.327) 109 -1.88 (17.649) 3.4 % -0.41 [ -0.68, -0.15 ]
H rslev-Petersen 2014 89 -33.1 (32.9) 91 -23.3 (31.3) 3.1 % -0.30 [ -0.60, -0.01 ]
Keystone 2004 206 -15.1 (21.94) 96 -7.87 (21.3) 3.7 % -0.33 [ -0.58, -0.09 ]
Keystone 2004 (3) 200 -16.55 (21.95) 96 -7.87 (21.3) 3.7 % -0.40 [ -0.64, -0.15 ]
Keystone 2009 89 -7.16 (8.58) 67 -2.16 (9.53) 2.8 % -0.55 [ -0.88, -0.23 ]
Keystone 2009 89 -7.3 (8.65) 66 -2.16 (9.53) 2.8 % -0.57 [ -0.89, -0.24 ]
Li 2013 132 -3.4 (9.4) 132 2.2 (11.2) 3.7 % -0.54 [ -0.79, -0.29 ]
Mittendorf 2007 (4) 99 -8.65 (10.19) 93 -3.33 (7.67) 3.2 % -0.59 [ -0.87, -0.30 ]
Moreland 1999 78 -25 (73.17) 40 -2 (63.2) 2.3 % -0.33 [ -0.71, 0.06 ]
Moreland 1999 (5) 76 -22 (63.2) 40 -2 (63.2) 2.3 % -0.31 [ -0.70, 0.07 ]
Pope 2012 851 -1.3 (3.16) 212 -0.5 (3.16) 5.0 % -0.25 [ -0.40, -0.10 ]
Smolen 2009a 246 -12.64 (16.53) 64 -2.76 (17.8) 3.3 % -0.59 [ -0.87, -0.31 ]
Smolen 2009a 246 -2.1 (2.1) 64 -0.5 (2) 3.2 % -0.77 [ -1.05, -0.49 ]
Smolen 2009a 246 -13.45 (19.52) 63 -2.76 (17.8) 3.3 % -0.56 [ -0.84, -0.28 ]
Smolen 2009a (6) 246 -2.1 (2.3) 63 -0.5 (2) 3.2 % -0.71 [ -0.99, -0.43 ]
Smolen 2009b 153 -6 (10.37) 76 -1 (8.89) 3.3 % -0.50 [ -0.78, -0.22 ]
Smolen 2009b 153 -5 (10.37) 77 -1 (8.89) 3.3 % -0.40 [ -0.68, -0.13 ]
Soubrier 2009 33 -33.5 (26.6) 32 -41.5 (29) 1.6 % 0.28 [ -0.20, 0.77 ]
Strand 2009 (7) 390 -14.4 (27.65) 99 -2.8 (15.92) 4.0 % -0.45 [ -0.67, -0.23 ]
-1 -0.5 0 0.5 1
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(. . . Continued)
Study or subgroup Biologics Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Strand 2009 393 -12.9 (25.77) 100 -2.8 (16) 4.0 % -0.42 [ -0.64, -0.20 ]
Strand 2012b 265 -14.6 (17.82) 254 -13.5 (17.82) 4.7 % -0.06 [ -0.23, 0.11 ]
Weinblatt 2003 75 -20.9 (20.9) 20 -5.4 (23.8) 1.6 % -0.71 [ -1.22, -0.21 ]
Weinblatt 2003 67 -18.3 (26.8) 21 -5.4 (23.8) 1.6 % -0.49 [ -0.99, 0.01 ]
Weinblatt 2003 69 -15.2 (20.5) 21 -5.4 (23.8) 1.6 % -0.46 [ -0.95, 0.04 ]
Weinblatt 2003 (8) 75 -10 (10.8) 20 -2.6 (10.1) 1.6 % -0.69 [ -1.19, -0.19 ]
Weinblatt 2003 67 -8.1 (11.2) 21 -2.6 (10.1) 1.6 % -0.50 [ -0.99, 0.00 ]
Weinblatt 2003 69 -5.8 (9.9) 21 -2.6 (10.1) 1.6 % -0.32 [ -0.81, 0.17 ]
Weinblatt 2013 395 -8 (10.8) 197 -2.5 (10.2) 4.7 % -0.52 [ -0.69, -0.34 ]
Subtotal (95% CI) 6087 2859 100.0 % -0.42 [ -0.49, -0.35 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 67.51, df = 31 (P = 0.00016); I2 =54%
Test for overall effect: Z = 11.40 (P < 0.00001)
2 Non-anti-TNF
Alten 2011 69 -4.4 (9.3) 23 0 (9.4) 2.0 % -0.47 [ -0.94, 0.01 ]
Alten 2011 64 -2.5 (9.2) 23 0 (9.4) 2.0 % -0.27 [ -0.75, 0.21 ]
Alten 2011 71 -3.5 (9.4) 23 0 (9.4) 2.0 % -0.37 [ -0.84, 0.10 ]
Cohen 2006 298 -13.97 (22.34) 201 -3.32 (21.09) 8.6 % -0.49 [ -0.67, -0.31 ]
Emery 2006 (9) 122 -6.02 (10.82) 61 -2.69 (7.42) 4.2 % -0.34 [ -0.65, -0.03 ]
Emery 2006 123 -6.71 (10.65) 61 -2.69 (7.42) 4.1 % -0.41 [ -0.72, -0.10 ]
Genovese 2005 (10) 258 -5.6 (10.96) 133 0 (10.96) 7.1 % -0.51 [ -0.72, -0.30 ]
Genovese 2008 724 -8.1 (10.53) 321 -3.3 (9.56) 11.6 % -0.47 [ -0.60, -0.34 ]
Kremer 2003 115 -7.9 (8.579) 60 -2.1 (8.727) 3.9 % -0.67 [ -0.99, -0.35 ]
Kremer 2003 (11) 105 -3.5 (8.198) 59 -2.1 (8.727) 3.9 % -0.17 [ -0.49, 0.15 ]
Kremer 2006 (12) 433 -7.3 (9.669) 219 -4.8 (9.875) 9.6 % -0.26 [ -0.42, -0.09 ]
Rigby 2011 250 -10.282 (27.15) 125 6.83 (11.27) 6.8 % -0.74 [ -0.96, -0.52 ]
Rigby 2011 249 -9.362 (27.25) 124 6.83 (11.27) 6.8 % -0.70 [ -0.92, -0.48 ]
Schiff 2008 (13) 165 -7 (10.5) 55 -3.5 (10) 4.2 % -0.34 [ -0.64, -0.03 ]
Schiff 2008 156 -8 (10) 55 -3.5 (10) 4.1 % -0.45 [ -0.76, -0.14 ]
Smolen 2008 (14) 172 -9.2 (10.8) 61 -4.4 (8.7) 4.5 % -0.46 [ -0.76, -0.17 ]
Smolen 2008 154 -8.4 (10.1) 61 -4.4 (8.7) 4.4 % -0.41 [ -0.71, -0.11 ]
Strand 2012a 161 -6.66 (9.77) 79 -3.03 (8.42) 5.1 % -0.39 [ -0.66, -0.12 ]
Strand 2012a 170 -9.07 (10.4) 79 -3.03 (8.42) 5.1 % -0.61 [ -0.89, -0.34 ]
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Study or subgroup Biologics Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 3859 1823 100.0 % -0.46 [ -0.53, -0.39 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 25.37, df = 18 (P = 0.12); I2 =29%
Test for overall effect: Z = 12.76 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.65, df = 1 (P = 0.42), I2 =0.0%
-1 -0.5 0 0.5 1
Favours biologics Favours control
(1) VAS - unpublished data supplied by author with note that ”only includes those with both baseline and post-treatment values”
(2) SF36-V; Reversed score so High=bad; Unpublished data provided by author
(3) SF36-V: Ad40 v ctrl; Half n entered for ctrl. Reversed score so High=bad
(4) FACIT-F; reversed score so High=bad; Unpublished data provided by author
(5) SF36-V: Etan 10mg v ctrl; Half n entered for ctrl. Reversed score so High=bad. Change sds calculated by review statistician.
(6) SF36-V; CZP 200mg Half n entered for ctrl. Reversed score so High=bad; Unpublished data provided by author
(7) Week 12 SF36-V; CZP 200mg v ctrl. Half n entered for ctrl. Reversed score so High=bad
(8) SF36-V; Ad 20mg Third of n entered for ctrl. Reversed score so High=bad; Unpublished data provided by author
(9) SF36-V; R500 v Ctrl. Half n entered for ctrl. Reversed score so High=bad; From Table 2 in Mease 2008
(10) VAS at 6mths. Values from Wells 2008.
(11) SF36-V: Ab 10mg v ctrl; Half n entered for ctrl. Reversed score so High=bad. Change sds calculated by review statistician
(12) SF36-V 12mths. Reversed score so High=bad. Change sds calculated by review statistician.
(13) SF-36V change scores at 6mths: Abat v ctrl; Half n entered for ctrl. Reversed score so High=bad Unpublished baseline data provided by author. Placebo arm stopped
at 6 months.
(14) FACIT-F; Toc 4mg v ctrl; Half n entered for ctrl. Reversed score so High=bad: CHECK N to be shown: Unpublished data provided by author
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. exp arthritis, rheumatoid/
2. ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat$ or reumat$ or revmarthrit$) adj3 (arthrit$
or artrit$ or diseas$ or condition$ or nodule$)).tw.
3. 1 or 2
4. exp Fatigue/
5. fatigue$.tw.
6. (tired$ or weary or weariness or exhaustion or exhausted).tw.
7. ((astenia or asthenic) and syndrome).tw.
8. ((lack or loss or lost) adj3 (energy or vigo?r)).tw.
9. (apath$ or lassitude or weak$ or letharg$).tw.
10. (feel$ adj3 (drained or sleep$ or sluggish)).tw.
11. vitality.tw.
12. or/4-11
13. randomized controlled trial.pt.
14. controlled clinical trial.pt.
15. randomized.ab.
16. placebo.ab.
17. drug therapy.fs.
18. randomly.ab.
19. trial.ab.
20. groups.ab.
21. or/13-20
22. (animals not (humans and animals)).sh.
23. 21 not 22
24. and/3,12,23
Appendix 2. EMBASE search strategy
1 exp rheumatoid arthritis/
2 ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat$ or reumat$ or revmarthrit$) adj3
(arthrit$ or artrit$ or diseas$ or condition$ or nodule$)).tw.
3 1 or 2
4 exp fatigue/
5 fatigue$.tw.
6 (tired$ or weary or weariness or exhaustion or exhausted).tw.
7 ((astenia or asthenic) and syndrome).tw.
8 ((lack or loss or lost) adj3 (energy or vigo?r)).tw.
9 (apath$ or lassitude or weak$ or letharg$).tw.
10 (feel$ adj3 (drained or sleep$ or sluggish)).tw.
11 vitality.tw.
12 or/4-11
13 3 and 12
14 random$.ti,ab.
15 factorial$.ti,ab.
16 (crossover$ or cross over$ or cross-over$).ti,ab.
17 placebo$.ti,ab.
18 (doubl$ adj blind$).ti,ab.
19 (singl$ adj blind$).ti,ab.
20 assign$.ti,ab.
21 allocat$.ti,ab.
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22 volunteer$.ti,ab.
23 crossover procedure.sh.
24 double blind procedure.sh.
25 randomized controlled trial.sh.
26 single blind procedure.sh.
27 or/14-26
28 exp animal/ or nonhuman/ or exp animal experiment/
29 exp human/
30 28 and 29
31 28 not 30
32 27 not 31
33 13 and 32
Appendix 3. CENTRAL search strategy
#1 MeSH descriptor Arthritis, Rheumatoid explode all trees
#2 ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat* or reumat* or revmarthrit*)
near/3 (arthrit* or artrit* or diseas* or condition* or nodule*)):ti,ab
#3 (#1 OR #2)
#4 MeSH descriptor Fatigue explode all trees
#5 fatigue*:ti,ab
#6 (tired* or weary or weariness or exhaustion or exhausted):ti,ab
#7 ((astenia or asthenic) and syndrome):ti,ab
#8 ((lack or loss or lost) near/3 (energy or vigor)):ti,ab
#9 (apath* or lassitude or weak* or letharg*):ti,ab
#10 (feel* near/3 (drained or sleep* or sluggish)):ti,ab
#11 vitality:ti,ab
#12 (#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11)
#13 (#3 AND #12)
Appendix 4. CINAHL search strategy
S75 S61 and S74
S74 S62 or S63 or S64 or S65 or S66 or S67 or S68 or S69 or S70 or S71 or S72 or S73
S73 TI Allocat* random* or AB Allocat* random*
S72 (MH “Quantitative Studies”)
S71 (MH “Placebos”)
S70 TI Placebo* or AB Placebo*
S69 TI Random* allocat* or AB Random* allocat*
S68 (MH “Random Assignment”)
S67 TI Randomi?ed control* trial* or AB Randomi?ed control* trial*
S66 AB singl* blind* or AB singl* mask* or AB doub* blind* or AB doubl* mask* or AB trebl* blind* or AB trebl* mask* or AB
tripl* blind* or AB tripl* mask*
S65 TI singl* blind* or TI singl* mask* or TI doub* blind* or TI doubl* mask* or TI trebl* blind* or TI trebl* mask* or TI tripl*
blind* or TI tripl* mask*
S64 TI clinical* trial* or AB clinical* trial*
S63 PT clinical trial
S62 (MH “Clinical Trials+”)
S61 S42 and S60
S60 S43 or S44 or S45 or S46 or S47 or S48 or S49 or S50 or S51 or S52 or S53 or S54 or S55 or S56 or S57 or S58 or S59
S59 ti vitality or ab vitality
S58 ab feel* N3 drain* or ab feel* N3 sleep* or ab feel* N3 sluggish
S57 ti feel* N3 drain* or ti feel* N3 sleep* or ti feel* N3 sluggish
88Biologic interventions for fatigue in rheumatoid arthritis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S56 ab apath* or ab lassitude or ab weak* or ab letharg*
S55 ti apath* or ti lassitude or ti weak* or ti letharg*
S54 ab lack N3 vigour or abloss N3 vigour or ab lost N3 vigour
S53 ti lack N3 vigour or ti loss N3 vigour or ti lost N3 vigour
S52 ab lack N3 vigor or ab loss N3 vigor or ab lost N3 vigor
S51 ti lack N3 vigor or ti loss N3 vigor or ti lost N3 vigor
S50 ti lack N3 vigor or ti loss N3 vigor or ab lost N3 vigor
S49 ti lack N3 energy or ti loss N3 energy or ti lost N3 energy
S48 ab astenia syndrome or ab asthenic syndrome
S47 ti astenia syndrome or ti asthenic syndrome
S46 ab tired* or weary or weariness or exhaustion or exhausted
S45 ti tired* or weary or weariness or exhaustion or exhausted
S44 ti fatigue* or ab fatigue*
S43 (MH “Fatigue+”)
S42 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19
or S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29 or S30 or S31 or S32 or S33 or S34 or S35 or S36 or S37 or
S38 or S39 or S40 or S41
S41 TI reumat* N3 nodule* or AB reumat* N3 nodule*
S40 TI reumat* N3 condition* or AB reumat* N3 condition*
S39 TI reumat* N3 diseas* or AB reumat* N3 diseas*
S38 TI reumat* N3 artrit* or AB reumat* N3 artrit*
S37 TI reumat* N3 arthrit* or AB reumat* N3 arthrit*
S36 TI revmarthrit* N3 nodule* or AB revmarthrit* N3 nodule*
S35 TI revmarthrit* N3 condition* or AB revmarthrit* N3 condition*
S34 TI revmarthrit* N3 diseas* or AB revmarthrit* N3 diseas*
S33 TI revmarthrit* N3 artrit* or AB revmarthrit* N3 artrit*
S32 TI revmarthrit* N3 arthrit* or AB revmarthrit* N3 arthrit*
S31 TI rheumat* N3 nodule* or AB rheumat* N3 nodule*
S30 TI rheumat* N3 condition* or AB rheumat* N3 condition*
S29 TI rheumat* N3 diseas* or AB rheumat* N3 diseas*
S28 TI rheumat* N3 artrit* or AB rheumat* N3 artrit*
S27 TI rheumat* N3 arthrit* or AB rheumat* N3 arthrit*
S26 TI revmatic N3 nodule* or AB revmatic N3 nodule*
S25 TI revmatic N3 condition* or AB revmatic N3 condition*
S24 TI revmatic N3 diseas* or AB revmatic N3 diseas*
S23 TI revmaticN3 artrit* or AB revmatic N3 artrit*
S22 TI revmatic N3 arthrit* or AB revmatic N3 arthrit*
S21 TI rheumatic N3 nodule* or AB rheumatic N3 nodule*
S20 TI rheumatic N3 condition* or AB rheumatic N3 condition*
S19 TI rheumatic N3 diseas* or AB rheumatic N3 diseas*
S18 TI rheumatic N3 artrit* or AB rheumatic N3 artrit*
S17 TI rheumatic N3 arthrit* or AB rheumatic N3 arthrit*
S16 TI revmatoid N3 nodule* or AB revmatoid N3 nodule*
S15 TI revmatoid N3 condition* or AB revmatoid N3 condition*
S14 TI revmatoid N3 diseas* or AB revmatoid N3 diseas*
S13 TI revmatoid N3 artrit* or AB revmatoid N3 artrit*
S12 TI revmatoid N3 arthrit* or AB revmatoid N3 arthrit*
S11 TI reumatoid N3 nodule* or AB reumatoid N3 nodule*
S10 TI reumatoid N3 condition* or AB reumatoid N3 condition*
S9 TI reumatoid N3 diseas* or AB reumatoid N3 diseas*
S8 TI reumatoid N3 artrit* or AB reumatoid N3 artrit*
S7 TI reumatoid N3 arthrit* or AB reumatoid N3 arthrit*
S6 TI rheumatoid N3 nodule* or AB rheumatoid N3 nodule*
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S5 TI rheumatoid N3 condition* or AB rheumatoid N3 condition*
S4 TI rheumatoid N3 diseas* or AB rheumatoid N3 diseas*
S3 TI rheumatoid N3 artrit* or AB rheumatoid N3 artrit* *
S2 TI rheumatoid N3 arthrit* or AB rheumatoid N3 arthrit*
S1 (MH “Arthritis, Rheumatoid+”)
Appendix 5. PsycINFO search strategy
1. rheumatoid arthritis/
2. ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat$ or reumat$ or revmarthrit$) adj3 (arthrit$
or artrit$ or diseas$ or condition$ or nodule$)).tw.
3. 1 or 2
4. Fatigue/
5. fatigue$.tw.
6. (tired$ or weary or weariness or exhaustion or exhausted).tw.
7. ((astenia or asthenic) and syndrome).tw.
8. ((lack or loss or lost) adj3 (energy or vigo?r)).tw.
9. (apath$ or lassitude or weak$ or letharg$).tw.
10. (feel$ adj3 (drained or sleep$ or sluggish)).tw.
11. vitality.tw.
12. or/4-11
Appendix 6. AMED search strategy
1. exp arthritis, rheumatoid/
2. ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat$ or reumat$ or revmarthrit$) adj3 (arthrit$
or artrit$ or diseas$ or condition$ or nodule$)).tw.
3. 1 or 2
4. exp Fatigue/
5. fatigue$.tw.
6. (tired$ or weary or weariness or exhaustion or exhausted).tw.
7. ((astenia or asthenic) and syndrome).tw.
8. ((lack or loss or lost) adj3 (energy or vigo?r)).tw.
9. (apath$ or lassitude or weak$ or letharg$).tw.
10. (feel$ adj3 (drained or sleep$ or sluggish)).tw.
11. vitality.tw.
12. or/4-11
13. 3 and 12
Appendix 7. Web of Science search strategy
Topic=((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat* or reumat* or revmarthrit*) and
(arthrit* or artrit* or diseas* or condition* or nodule*)) ANDTopic=(fatigue* or tired* or weary or weariness or exhaustion or exhausted
or astenia syndrome or asthenic syndrome or apath* or
lassitude or weak* or
(lack or loss or lost) and (letharg* or energy or vigoor* or vigour*) or
Feel* and (drained or sleep* or sluggish)
(trial* or random* or placebo* or control* or double or treble or triple or blind* or mask* or allocat* or prospective* or volunteer*or
comparative or evaluation or follow-up or followup)
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Appendix 8. Dissertation Abstracts search strategy
(rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat* or reumat* or revmarthrit*) in citation and
abstract
AND (fatigue* or tired* or weary or weariness or exhaustion or exhausted or astenia syndrome or asthenic syndrome or apath* or
lassitude or weak* or letharg* or energy or vigoor* or vigour* or drained or sleep* or sluggish) in citation and abstract
C O N T R I B U T I O N S O F A U T H O R S
All authors contributed to the initial draft protocol for the review. Fiona Cramp, Celia Almeida and Sarah Hewlett worked in collab-
oration on refining all parts of the final protocol, incorporating comments from members of the wider review group (with particular
thanks to Dr Jon Pollock). Robin Christensen provided advice and performed statistical analyses. Ernest Choy drafted the review.
D E C L A R A T I O N S O F I N T E R E S T
At the time of protocol development Sarah Hewlett was in receipt of a small unrestricted educational grant from GlaxoSmithKline to
partially fund a PhD studentship on fatigue measurement in RA and also undertaking an RCT of cognitive behavioural therapy (CBT)
for the self-management of RA fatigue, funded by the Arthritis Research Campaign. During the full review process Sarah Hewlett
has been undertaking an RCT of CBT for the self-management of RA fatigue by the clinical team, funded by the National Institutes
for Health Research. She has received small consultancy fees from UCB Pharmaceuticals and Bristol Myers Squibb to advise on the
translation of the Bristol RA Fatigue Scales, and small, unrestricted educational grants from Pfizer to deliver training days for staff, in
which non-pharmacological management of fatigue was included. These associations reflect our large programme of research in fatigue
into RA but do not constitute a conflict of interests. Robin Christensen has received consulting fees paid to the Parker Institute from
Abbott/AbbVie, Axellus A/S, Bristol-Myers Squibb, Cambridge Weight Plan, Norpharma, Pfizer and Roche; speakers fees paid to the
Parker Institute from Axellus A/S, Cambridge Weight Plan, Mundipharma, Roche, and Rottapharm-MEDA; research grants paid to
the Parker Institute from Abbott/AbbVie, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge
Weight Plan, Ipsen, Laboratoires Expanscience, MSD, Mundipharma/Norpharma, Pfizer, and Roche. John Kirwan has been a paid
adviser to the Royal Pharmaceutical Society and British Medical Association publication the British National Formulary during the
time of this review. He also had unconditional educational grants from Horizon Pharma for the cost of attending the American College
of Rheumatology Annual Scientific Meeting in 2013 and the cost of travel to the American College of Rheumatology Annual Scientific
Meeting in 2014. Ernest Choy and Cardiff University has received research grants from Ferring Pharmaceuticals, Novimmune, Pfizer,
Roche, and UCB. Ernest Choy has received payment as member of advisory boards and lecture fees from Amgen, Biogen, BMS,
Celgene, Chugai Pharma, Eli Lilly, Ferring Pharmacuetical, Hospita, Jenssen, MSD, Napp, Novimmune, Pfizer, Regeneron, Roche,
Sanofi, Tonix and UCB. Trudie Chalder is author of self help books for chronic fatigue and receives some royalties. Celia Almeida,
Fiona Camp and Jon Pollock have no conflict of interest to declare.
S O U R C E S O F S U P P O R T
Internal sources
• None, Other.
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External sources
• None, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the protocol, we did not include sensitivity analysis. However, as there was statistically significant heterogeneity, we performed
sensitivity analyses to examine to explore the potential cause(s) of heterogeneity: dose-ranging studies trials in participants who had
failed previous biologic and disease duration.Robin Christensen has received consulting fees paid to the Parker Institute from Abbott/
AbbVie, Axellus A/S, Bristol-Myers Squibb, Cambridge Weight Plan, Norpharma, Pfizer and Roche; speakers fees paid to the Parker
Institute from Axellus A/S, Cambridge Weight Plan,Mundipharma, Roche, and Rottapharm-MEDA; research grants paid to the Parker
Institute from Abbott/AbbVie, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight
Plan, Ipsen, Laboratoires Expanscience, MSD, Mundipharma/Norpharma, Pfizer, and Roche.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Abatacept [therapeutic use]; Adalimumab [therapeutic use]; Antibodies, Monoclonal [therapeutic use]; Antibodies, Monoclonal, Hu-
manized [therapeutic use]; Antirheumatic Agents [∗therapeutic use]; Arthritis, Rheumatoid [complications; ∗drug therapy]; Cer-
tolizumab Pegol [therapeutic use]; Etanercept [therapeutic use]; Fatigue [∗drug therapy; etiology; therapy]; Immunosuppressive Agents
[∗therapeutic use]; Infliximab [therapeutic use]; Interferon-gamma [antagonists & inhibitors]; Randomized Controlled Trials as Topic;
Rituximab [therapeutic use]
MeSH check words
Humans
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